Light-Activated Compounds by Glazer, Edith C. & Heidary, David K.
University of Kentucky
UKnowledge
Chemistry Faculty Patents Chemistry
3-22-2016
Light-Activated Compounds
Edith C. Glazer
University of Kentucky, ec.glazer@uky.edu
David K. Heidary
University of Kentucky, david.heidary@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/chemistry_patents
Part of the Chemistry Commons
This Patent is brought to you for free and open access by the Chemistry at UKnowledge. It has been accepted for inclusion in Chemistry Faculty Patents
by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Recommended Citation
Glazer, Edith C. and Heidary, David K., "Light-Activated Compounds" (2016). Chemistry Faculty Patents. 35.
https://uknowledge.uky.edu/chemistry_patents/35
c12) United States Patent 
Glazer et al. 
(54) LIGHT-ACTIVATED COMPOUNDS 
(71) Applicant: University of Kentucky Research 
Foundation, Lexington, KY (US) 
(72) Inventors: Edith C. Glazer, Lexington, KY (US); 
David K. Heidary, Lexington, KY (US) 
(73) Assignee: University of Kentucky Research 
Foundation, Lexington, KY (US) 
( *) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 0 days. 
(21) Appl. No.: 14/217,307 
(22) Filed: Mar. 17, 2014 
Related U.S. Application Data 
(60) Provisional application No. 61/799,678, filed on Mar. 
15, 2013. 
(51) Int. Cl. 
A61K 311555 
C07F 15100 
(52) U.S. Cl. 
(2006.01) 
(2006.01) 
CPC .................................. C07F 1510053 (2013.01) 
(58) Field of Classification Search 
USPC ................................. 514/185, 184; 546/10, 2 
See application file for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
5,608,059 A 
5,714,089 A 
6,979,681 B2 
8,063,216 B2 
2005/0181443 A1 
3/1997 Wear eta!. 
211998 Bard eta!. 
12/2005 Morris eta!. 
1112011 Etchenique eta!. 
8/2005 Sun eta!. 
111111 1111111111111111111111111111111111111111111111111111111111111 
US009290528B 1 
(10) Patent No.: US 9,290,528 Bl 
Mar.22,2016 (45) Date of Patent: 
2006/0111335 A1 
2007/0082881 A1 
2007/0161069 A1 
2008/0176940 A1 
2012/0116287 A1 
5/2006 Morrison eta!. 
4/2007 MacDonnell et a!. 
7/2007 Rose eta!. 
7/2008 Etchenique eta!. 
5/2012 Etchenique eta!. 
OTHER PUBLICATIONS 
Wachter, E. et al.: Light-activated ruthenium complexes photobind 
DNA and are cytotoxic in the photodynamic therapy window. Chern. 
Commun., vol. 48, pp. 9649-9651, 2012.* 
Yu, H-J. eta!.: Synthesis, visible light photocleavage, antiprolifera-
tive and cellular uptake properties of ruthenium complex. Eur. J. 
Medicin. Chern., vol. 55, pp. 14154, 2012.* 
Sun, Y. eta!.: Efficient DNA photocleavage by [Ru(bpy)2(dppn)]2+ 
with visible light. Chern. Commun., vol. 46, pp. 2426-2428, 2010.* 
Monro, S. et al.: Photobiological activity ofRu(II) based on (pyren-
1-yl)ethynyl derivatives of 1,10-phenanthroline. Inorganic Chern., 
vol. 49, pp. 2889-2900, 2010.* 
Juris, et al., Ru(II) Polypyridine Complexes: Photopi3ysics, 
Photochemwt'ry, Eleci?Rochemistry, and Chemilumine Scence; 
Coordination Chemistry Reviews, 84 (1988) 85-277. 
* cited by examiner 
Primary Examiner- Charanjit Aulakh 
(74) Attorney, Agent, or Firm- Stites & Harbison PLLC; 
Mandy Wilson Decker 
(57) ABSTRACT 
The presently-disclosed subject matter includes light-acti-
vated ruthenium compounds. In some embodiments the com-
pounds release one or more ligands when exposed to light, 
and in specific embodiments the light includes a wavelength 
of about 500 nm to about 1000 nm. The present compounds 
can also comprise an overall charge, wherein the overall 
charge can be a positive overall charge or a negative overall 
charge. Further still, embodiments include methods of treat-
ing cancer in a subject by administering a compound and then 
exposing a site of the subject to light. 
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LIGHT-ACTIVATED COMPOUNDS 
RELATED APPLICATIONS 
2 
FIG. 2 includes images showing an ellipsoid plot (at 50% 
probability) of2 (left) and a capped stick overlay of2 (right). 
Both biquinoline ligands have a 20° bend from the ideal 
octahedral plane, where the N(3)-N( 4) biquinoline has a 12° 
twist about the C---C bond between the two quinolones and 
the N(1)-N(2) biquinoline does not. 
This applications claims priority from U.S. Provisional 5 
Application Ser. No. 61/799,678, filed Mar. 15, 2013, the 
entire disclosure of which is incorporated herein by this ref- FIG. 3 includes a reaction scheme showing the photo-
substitution reaction of 2 in H20, and further includes charts 
showing the associated UV /Vis absorption spectra at different 
10 time points in the reaction under blue light, where the inset 
shows the kinetic fit for the reaction. 
erence. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to light-ac-
tivated compounds. In particular, presently-disclosed subject 
matter relates to light -activated ruthenium compounds as well 
as methods for using the same. 
INTRODUCTION 
FIGS. 4A to 4E includes images showing agarose gel elec-
trophoresis for the dose response ofl (left) and 2 (right) with 
15 
40 flg/mL pUC19 plasmid in the (Figure A) dark and after 
irradiation with (FIG. 4B) blue (>400 nm), (FIG. 4C) green 
(>450 nm), (FIG. 4D) red (>600 nm), and (FIG. 4E) near-IR 
(>650nm)light. Lane 1: DNA ladder; Lane2: EcoRI; Lane3: 
Cu(OP)2 ; Lane 4:0 f.LM; Lane 5: 15 f.LM; Lane 6: 30 f.LM; Lane 
20 7: 60 f.LM; Lane 8: 125 f.LM; Lane 9: 250 f.LM; Lane 10: 500 f.LM; 
Lane 11: 1,000 f.LM; Lane 12: DNA Ladder. 
Photoactivation is an elegant method to convert non-toxic 
prodrugs to active cytotoxic species in a spatially and tempo-
rally controlled mauner. Photoactivation provides a mecha-
nism to discriminate between malignant tissues of tumors and 
the surrounding healthy tissues, potentially reducing the 
dose-limiting side effects incurred with standard chemothera- 25 
pies. Photodynamic therapy (PDT) uses this light-targeted 
approach, and has been successfully applied in the treatment 
FIG. 5 includes charts showing the UVNis absorption of 4 
following photoejection in buffer (10 mM phosphate buffer, 
pH 7 .5), where the inset shows the photoejection kinetics. 
FIGS. 6A to 6D includes images showing agarose gels 
electrophoresis for 40 flg/mL pUC19 plasmid (1 0 mM phos-
phate buffer, pH 7.5)with(FIG. 6A) 3, (FIG. 6B) 4, and(FIG. 
6C) 5, where Lanes 1 and 12: DNA molecular weight stan-
dard, Lane2: linearpUC19, Lane3: relaxed circle (Cu(phen)2 
of various cancers, notably of the lung, esophagus, and skin. 
PDT commonly requires a photosensitizer such as a por-
phyrin to generate singlet oxygen eo2), which is the actual 
toxic moiety. However, this requirement for oxygen has lim-
ited the utility of PDT, due to the hypoxic nature of many 
tumors. Known porphyrin-type organic photo sensitizers used 
in PDT also have other poor chemical characteristics, and 
suffer from photo bleaching, poor solubility, and retention in 
tissues, causing protracted photosensitivity. 
In light of these drawbacks, several groups are investigat-
ing photoactive metal compounds (complexes) as alternative 
PDT agents. For instance, ruthenium polypyridyl compounds 
have tunable absorption properties, and can induce 10 2 -me-
diated DNA photocleavage when exposed to UV to visible 
light. Some ruthenium agents also can act via oxygen-inde-
pendent mechanisms, allowing for activity in hypoxic tissues. 
However, unlike organic PDT sensitizers, known metal com-
pounds are not activated, and therefore are not cytotoxic, 
within the "therapeutic window" for PDT, which includes red 
and near infrared (IR) light from 600-1100 urn. 
Hence, there remains a need for improved PDT agents, and 
specifically compounds that are thermally inert and that can 
be triggered by low energy, visible light to generate toxic 
species for use as, for example, chemotherapeutics. There are 
remains a need for agents that are easy to synthesize, have a 
flexible design that can be modified without unduly compro-
mising efficacy, and retain activity in the presence ofbiologi-
cal reducing agents, such as glutathione. Further still, there 
remains a need for agents having structural motifs that are 
distinct from those of known agents (e.g., square planar plati-
num compounds) so that they may retain efficacy in subjects 
that have otherwise developed resistance to known drugs, 
such as cisplatin and its analogues. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 includes structures showing Ru(II) complexes, and 
further includes charts showing the UV/Vis absorption spec-
tra of 1 (black) and 2 (gray), where the inset shows the 
absorption in a region of the PDT window (600 nm-900 nm). 
30 reaction with pUC19), Lanes 4-11: 0, 7 .5, 15, 30, 60, 120, 
240, and 500 f.LM compound; and further includes agarose gel 
electrophoresis showing (FIG. 6D) Lanes 1 and 14: DNA 
molecular weight standard, Lane 2: pUC19, Lane3: pUC19+ 
40 mM GSH. Cisplatin (30 f.LM, lanes 4-8) and compound 4 
35 (30 f.LM, lanes 9-13) were dosed with GSH: lanes 4-8 and 
9-13: 0.01, 0.1, 1, 10, 40 mM GSH. 
FIGS. 7A to 7D includes charts showing the cytotoxicity 
dose responses of metal complexes in HL60 cells for (FIG. 
7A)cisplatin, (FIG. 7B)3, (FIG. 7C) 4, and(FIG. 7D) 5. Dark 
40 conditions (circles); irradiated samples, 3 min>450 nm light 
(squares). (n=3). 
FIGS. SA to SB includes charts showing the cytotoxicity 
dose responses in A549 tumor spheroids for (FIG. SA) com-
pound 4 (dark conditions, circles; irradiated samples, 3 
45 min>450 nm light, squares), and (FIG. SB) cisplatin (dark 
conditions, squares; ALA, irradiated samples, 3 min>450 nm 
light, circles). (n=3.) 
FIGS. 9A and 9B include (FIG. 9A) a scheme for the 
selective photoejection of dmdppz from 8 with A.>400 nm 
50 light, and (FIG. 9B) a chart ofUVNis monitoring of photo-
ejection in the presence of CT DNA (1 0: 1 nucleotide: 8), 
where the kinetic fit for the photochemical reaction is shown 
in the inset. 
FIG. 10 includes images showing the crystal structure of 
55 racemic (left) compound 7 and (right) compound 8, where 
ellipsoids are drawn to 50% probability and hydrogen atoms 
are excluded for clarity. 
FIG. 11 includes an illustration showing a Jablonski dia-
gram for compound 8 (BS=Bright State; DS=Dark State; NR 
60 Decay=nonradiative decay). 
FIGS. 12A to 12D includes images showing agarose gel 
electrophoresis of 40 flg/ml pUC19 with increasing concen-
trations of (FIG. 12A) 9 and (FIG. 12B) 10 in the dark or 
irradiated (lanes 1 and 12, DNA molecular weight standard; 
65 lane 2, linear (reaction with EcoR1); lane 3, relaxed circle 
(reaction with Cu(phen)2); lanes 4-11, 0, 7 .5, 15, 30, 60, 120, 
240, and 500 f.LM compound); and further includes charts 
US 9,290,528 Bl 
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showing the cytotoxicity dose response of (FIG. 12C) 1 and 
(FIG.12D) 10 in the dark (open squares) or irradiated (closed 
circles). 
FIGS. 13A and 13 B includes apoptome micrographs show-
ing subcellular localization of 9 and 10 at 8 hours, where 
(FIG. 13A) Mitotracker Green FM was used to image mito-
chondria, and (FIG. 13B) Lysotracker Green DND-26 was 
used to image lysosomes. 
4 
C(O)R, S, S(R), 0, O(R), and P, wherein R is selected from H, 
OH, alkyl, and aryl, and m is -6 to +6. 
As used herein, the term "substituted" is contemplated to 
refer to compounds that have been modified with any and all 
permissible substituents. In a broad aspect, the permissible 
substituents include acyclic and cyclic, branched and 
unbranched, carbocyclic and heterocyclic, and aromatic and 
nonaromatic substituents of organic compounds. Illustrative 
FIGS. 14A to 14D includes charts showing mitochondrial 
potential and cell viability ofHL60 cells as a function of time 10 
for (FIG. 14A) 9, dark, (FIG. 14B) 9, irradiated; (FIG. 14C) 
substituents include, for example, those described below. The 
permissible substituents can be one or more and the same or 
different for appropriate compounds. For example, in some 
embodiments the compounds that comprise polypyridyl 
ligands that have been substituted with alkyl substituents 
and/or any other permissible substituents described herein. In 
10, dark; (FIG.14D) 10, irradiated. TMRE was used to quan-
tify membrane potential; values are relative to a no-com-
pound control value of 100. 
15 certain embodiments the present compounds are substituted 
with a substituent that can induced strain in the compounds. 
This disclosure is not intended to be limited in any manner by 
the permissible substituents of the present compounds. 
FIGS. 15A and 15B include images of (FIG. 15A) a West-
em blot analysis of cleaved PARP, Caspase 3, and Pro-
Caspase 3, where GAPDH was used as a loading control, and 
(FIG. 15B) agarose gel electrophoresis of genomic DNA 
harvested from HL60 cells after treatment with various agents 20 
(Lanes 1 and 9; ladder; 2, no compound control; 3, 10% 
EtOH, 24 hours (necrosis control); 4, cisplatin, 24 hours 
(apoptosis control); 5, 9+hv, 8 hours; 6, 9-hv, 8 hours; 7, 
10+hv, 24 hours; 8, 10-hv, 24 hours). 
Also, the terms "substitution" or "substituted with" include 
the implicit proviso that such substitution is in accordance 
with permitted valence of the substituted atom and the sub-
stituent, and that the substitution results in a stable com-
pound, e.g., a compound that does not spontaneously undergo 
transformation such as by rearrangement, cyclization, elimi-
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. Modi-
fications to embodiments described in this document, and 
other embodiments, will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the specific details of the described exemplary 
embodiments, is provided primarily for clearness of under-
standing and no unnecessary limitations are to be understood 
therefrom. In case of conflict, the specification of this docu-
ment, including definitions, will control. 
The presently-disclosed subject matter includes light-acti-
vated metal compounds, and in particular, certain embodi-
ments include ruthenium (Ru) compounds. In some embodi-
ments of ruthenium compounds comprise a ruthenium metal 
core and one or more ligands, wherein one or more ligands are 
released from the ruthenium metal center when the com-
pound is exposed to light. As used herein, the terms "com-
pound," "complex," and the like are used interchangeably to 
refer to embodiments of light-activated metal substances. 
More specifically, the presently-disclosed subject matter 
includes compounds having structures represented by the 
following formula: 
+1-m 
wherein Xu X2 , and X3 , the same or different from one 
another, are selected from bidentate nitrogen heterocycles, 
metallocycles, or a combination thereof, and are optionally 
substituted with one or more of alkyl, aryl, amine, C(O), 
25 nation, etc. 
In defining various terms, "A1,""A2 ,""A3 ," and "A4 ", or the 
like, are used herein as generic symbols to represent various 
specific substituents. These symbols can be any substituent, 
not limited to those disclosed herein, and when they are 
30 defined to be certain substituents in one instance, they can, in 
another instance, be defined as some other substituents. 
The term "alkyl" as used herein is a branched or 
unbranched saturated hydrocarbon group of 1 to 24 carbon 
atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 
35 isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neo-
pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, 
hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group 
can be cyclic or acyclic. The alkyl group can be branched or 
unbranched. The alkyl group can also be substitutedorunsub-
40 stituted. For example, the alkyl group can be substituted with 
one or more groups including, but not limited to, optionally 
substituted alkyl, cycloalkyl, alkoxy, amino, ether, halide, 
hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein. 
A "lower alkyl" group is an alkyl group containing from one 
45 to six (e.g., from one to four) carbon atoms. 
Throughout the specification "alkyl" is generally used to 
refer to both unsubstituted alkyl groups and substituted 
alkyl groups; however, substituted alkyl groups are also spe-
cifically referred to herein by identifYing the specific substitu-
50 ent(s) on the alkyl group. For example, the term "halogenated 
alkyl" specifically refers to an alkyl group that is substituted 
with one or more halide, e.g., fluorine, chlorine, bromine, or 
iodine. The term "alkoxyalkyl" specifically refers to an alkyl 
group that is substituted with one or more alkoxy groups, as 
55 described below. The term "alkylamino" specifically refers to 
an alkyl group that is substituted with one or more amino 
groups, as described below, and the like. When "alkyl" is used 
in one instance and a specific term such as "alkylalcohol" is 
used in another, it is not meant to imply that the term "alkyl" 
60 does not also refer to specific terms such as "alkylalcohol" 
and the like. 
This practice is also used for other groups described herein. 
That is, while a term such as "cycloalkyl" refers to both 
unsubstituted and substituted cycloalkyl moieties, the substi-
65 tuted moieties can, in addition, be specifically identified 
herein; for example, a particular substituted cycloalkyl can be 
referred to as, e.g., an "alkylcycloalkyl." Similarly, a substi-
US 9,290,528 Bl 
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tuted alkoxy can be specifically referred to as, e.g., a "halo-
genated alkoxy," a particular substituted alkenyl can be, e.g., 
an "alkenylalcohol," and the like. Again, the practice of using 
a general term, such as "cycloalkyl," and a specific term, such 
as "alkylcycloalkyl," is not meant to imply that the general 
term does not also include the specific term. 
6 
The term "cycloalkyl" as used herein is a non-aromatic 
carbon-based ring composed of at least three carbon atoms. 
Examples of cycloalkyl groups include, but are not limited to, 
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, 
and the like. The term "heterocycloalkyl" is a type of 
cycloalkyl group as defined above, and is included within the 
meaning of the term "cycloalkyl," where at least one of the 
carbon atoms of the ring is replaced with a heteroatom such 
Reference to any of the compounds described here also 
includes reference to any pharmaceutically acceptable 
derivative thereof, regardless of whether this is expressly 
stated for each compound. The term "derivative" is used 
herein to refer to a compound having a structure derived from 
the structure of a parent compound (e.g., a compounds dis-
closed herein) and whose structure is sufficiently similar to 
those disclosed herein and based upon that similarity, would 
be expected by one skilled in the art to exhibit the same or 
10 similar activities and utilities as the claimed compounds, or to 
induce, as a precursor, the same or similar activities and 
utilities as the claimed compounds. Exemplary derivatives 
include salts, esters, amides, salts of esters or amides, and 
15 
N -oxides of a parent compound. The term "pharmaceutically 
acceptable" describes a material that is not biologically or 
otherwise undesirable, i.e., without causing an unacceptable 
level of undesirable biological effects or interacting in a del-
eterious marmer. 
as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. 
The cycloalkyl group and heterocycloalkyl group can be sub-
stituted or unsubstituted. The cycloalkyl group and heterocy-
cloalkyl group can be substituted with one or more groups 
including, but not limited to, optionally substituted alkyl, 20 
cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, 
sulfo-oxo, or thiol as described herein. 
In this regard, the term "heterocycle," as used herein refers 
to single and multi-cyclic aromatic or non-aromatic ring sys-
tems in which at least one of the ring members is other than 25 
carbon. Heterocycle includes pyridine, pyrimidine, furan, 
thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, 
thiazole, imidazole, oxazole, including, 1,2,3-oxadiazole, 
1,2,5-oxadiazole and 1,3,4-oxadiazole, thiadiazole, includ-
ing, 1,2,3-thiadiazole, 1,2,5-thiadiazole, and 1,3,4-thiadiaz- 30 
ole, triazole, including, 1,2,3-triazole, 1,3,4-triazole, tetra-
zole, including 1,2,3,4-tetrazole and 1,2,4,5-tetrazole, 
pyridine, pyridazine, pyrimidine, pyrazine, triazine, includ-
ing 1,2,4-triazine and 1,3,5-triazine, tetrazine, including 1,2, 
4,5-tetrazine, pyrrolidine, piperidine, piperazine, morpho- 35 
line, azetidine, tetrahydropyran, tetrahydrofuran, dioxane, 
and the like. 
In some embodiments at least one of Xu X2 , and X3 (i.e., 
ligands) are released when the compound is exposed to light. 
In this regard, in some embodiments the compounds com-
prise at least one ligand that is inherently strain-inducing 
and/or a ligand that includes a strain-inducing group (sub-
stituent). The term "strain-inducing group" generally refers to 
the general characteristic of a group that can create a steric 
clash in a compound. In specific embodiments "strain-induc-
ing" refers to the characteristic of a compound having bond 
lengths and/or bond angles that deviate by 5% or more rela-
tive to the ideal bond lengths and/or bond angles determined 
by VSEPR theory. Such determinations can be made by ana-
lyzing the crystal structure of a compound, for example. 
Thus, in some embodiments at least one of Xu X2 , and X3 
can be a strain-inducing ligand that produces a steric clash in 
the compound, which can facilitate release of the ligands 
upon being exposed to certain light. In some instances the 
term strain inducing is used to refer to a group or substituent 
that gives rise to strain-inducing properties. For example, a 
The term "aryl" as used herein is a group that contains any 
carbon-based aromatic group including, but not limited to, 
benzene, naphthalene, phenyl, biphenyl, phenoxybenzene, 
and the like. The term "aryl" also includes "heteroaryl," 
which is defined as a group that contains an aromatic group 
that has at least one heteroatom incorporated within the ring 
40 ligand can be substituted with one or more strain-inducing 
groups that impart a strain-inducing characteristic to the 
ligand. In specific embodiments the strain-inducing group is 
located in a ligand at a position ortho to the chelating nitrogen 
of the aromatic group. Examples ofheteroatoms include, but 
are not limited to, nitrogen, oxygen, sulfur, and phosphorus. 45 
Likewise, the term "non-heteroaryl," which is also included 
in the term "aryl," defines a group that contains an aromatic 
group that does not contain a heteroatom. The aryl group can 
be substituted or unsubstituted. The aryl group can be substi-
tuted with one or more groups including, but not limited to, 50 
optionally substituted alkyl, cycloalkyl, alkoxy, alkenyl, 
cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, alde-
hyde, amino, carboxylic acid, ester, ether, halide, hydroxy, 
ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described 
herein. The term "biaryl" is a specific type of aryl group and 55 
is included in the definition of"aryl." Biaryl refers to two aryl 
groups that are bound together via a fused ring structure, as in 
naphthalene, or are attached via one or more carbon-carbon 
bonds, as in biphenyl. 
The term "aldehyde" as used herein is represented by a 60 
formula ---C(O)H. Throughout this specification "C(O)" is a 
short hand notation for a carbonyl group, i.e., C=O. 
The terms "amine" or "amino" as used herein are repre-
sented by a formula NA1A2A3 , where A\ A2 , andA3 can be, 
independently, hydrogen or optionally substituted alkyl, 65 
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, 
aryl, or heteroaryl group as described herein. 
of a bidentate nitrogen heterocycle. 
Some exemplary ligands are represented by the formula: 
wherein each R1 is independently selected from H, amine, 
amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03H, R4 
being H, alkyl, or aryl, or wherein R1 and R3 taken together 
with the carbon atoms to which they are bonded, form a 
substituted or unsubstituted ring containing about 4-6 ring 
carbon atoms that optionally include one or more N, each R2 
isH, amine, amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or 
S03H, each R3 is independently selected from H, amine, 
amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, or 
wherein R3 and R4 taken together with the carbon atoms to 
which they are bonded, form a substituted or unsubstituted 
ring containing about 4-6 ring carbon atoms that optionally 
include one or more N, and each R4 isH, amine, amide, alkyl, 
aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H. 
US 9,290,528 Bl 
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In some embodiments exemplary ligands are represented 
by the formula: 
10 
wherein each R1 is independently selected from H, amine, 
amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, R4 
being H, alkyl, or aryl, or wherein R1 and R3 taken together 
with the carbon atoms to which they are bonded, form a 15 
substituted or unsubstituted ring containing about 4-6 ring 
carbon atoms that optionally include one or more N, and each 
R2 isH, amine, amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, 
or S03 H. 
In other embodiments exemplary ligands are represented 
by the formula: 
20 
25 
30 
wherein R1 and R2 , the same or different from one another, are 35 
any group other than H. In some embodiments the strain-
inducing group (e.g., R1 and R2 ) is an alkyl, such as a methyl 
group. Other examples of strain-inducing groups include, but 
are not limited to, cycloalkyl, phenyl, aryl, and heteroatom 
(e.g., N, 0, S, P, Cl, Br, I, etc.) substituents. The ligands can be 40 
selected from the group consisting of, but are not limited to, 
2,2'-bipyridyl, dipyrido[3,2-f:2',3'-h]-quinoxaline, 1,10-
phenanthroline, hydroxyquinoline, and the like. 
A non-limiting list of exemplary ligands, both strain-in- 45 
ducing and not, that can be incorporated in compounds of the 
presently-disclosed subject matter also include those repre-
sented by the following structures: 
50 
55 
60 
65 
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-continued 
~ ;=( HOOC COOH 
1()----\-_jj b-d 
o=Q. d-b 
tBu tBu, 
b-d 
HOOC COOH 
9 
-continued 
0 
0 
0 
H2Nn(H2C)HN 
0 
~ 
N N 
US 9,290,528 Bl 
10 
20 
25 
30 
NH(CH2)nNH2, 
35 
0 
40 
NH(CH2)nNH2, 
45 
0 
50 
55 
~ 
N N 
60 
65 
10 
-continued 
Q f ~@-a 
N N \ j 
0 0 
and 
0 0 
In some embodiments the compound comprises a structure 
according to at least one of the following formula: 
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-continued 
In some embodiments the light-activated properties of the 
compounds can be tuned based on the selection of ligands 
and/or substituents, and the compounds can be tuned to be 
photo-activated (i.e., release ligands) when exposed to light 
having particular wavelengths. In this regard, the term "light" 
is used herein to refer to any electromagnetic radiation that 
can activate a compound. In some embodiments light 
includes ultraviolet light, visible light, near infrared light 
(NIR), or infrared light (IR). Compounds activated by rela-
tively long wavelength light may be particularly well suited 
for targeting tumors and the like that are deep in tissues, since 
light generally penetrates deeper into tissues as the wave-
length increases. Some embodiments of compounds have the 
surprising and unexpected advantage of being photo-acti-
vated by light having wavelengths greater than 500 nm. 
14 
More specifically, light can refer to electromagnetic radia-
tion having a wavelength of about 350 nm to about 500 nm. In 
other embodiments light includes energy having a wave-
length of about 500 nm to about 1000 nm. In specific embodi-
5 ments light can refer to energy having a wavelength of about 
300 nm, about 350 nm, about 450 nm, about 500 nm, about 
550 nm, about 600 nm, about 650 nm, about 700 nm, about 
750 nm, about 800 nm, about 850 nm, about 900 nm, about 
950 nm, or about 1000 nm. In other specific embodiments 
10 light can refer to energy having a wavelength greater than 
about 300 nm, greater than about 350 nm, greater than about 
450 nm, greater than about 500 nm, greater than about 550 
nm, greater than about 600 nm, greater than about 650 nm, 
greater than about 700 nm, greater than about 7 50 nm, greater 
15 than about 800 nm, greater than about 850 nm, greater than 
about 900 nm, or greater than about 950 nm. 
Still further, some embodiments of compounds also com-
prise a targeting agent and/or a therapeutic agent. Folate, 
estrogen, and eroltinib are examples of a targeting agent that 
20 can be used in embodiments of the presently-disclosed com-
pounds. Those of ordinary skill will appreciate other small 
molecule targeting agents that can be incorporated into the 
present compounds. Additionally, hydroxyquinoline is an 
example of a therapeutic agent that can be used in embodi-
25 ments of the presently-disclosed compounds. In some 
embodiments the photo-releasable ligands of the embodied 
compounds can be a targeting agent and/or a therapeutic 
agent. 
The presently-disclosed compounds can further comprise 
30 an overall charge. In some embodiments the overall charge is 
-6 to +6. The overall charge can depend on the ligands incor-
porated into embodied compounds. For example, in some 
embodiments ligands comprising carboxylic acid and/or sul-
fonic acid result in compounds that have negative (e.g., -2) 
35 overall charges at physiological pH. In specific embodiments 
the present compounds comprise an overall charge of -6, -5, 
-4, -3, -2, -1, neutral charge,+ 1, +2, +3, +4, +5, or +6. Those 
of ordinary skill will appreciate that depending on the ligands 
of the present compounds, the overall charge may also be less 
40 than about -6 or greater than about +6. 
The presently-disclosed subject matter further includes 
pharmaceutical compositions of the compounds as disclosed 
herein, and further includes a pharmaceutically-acceptable 
carrier. In this regard, the term "pharmaceutically acceptable 
45 carrier" refers to sterile aqueous or nonaqueous solutions, 
dispersions, suspensions or emulsions, as well as sterile pow-
ders for reconstitution into sterile injectable solutions or dis-
persions just prior to use. Proper fluidity can be maintained, 
for example, by the use of coating materials such as lecithin, 
so by the maintenance of the required particle size in the case of 
dispersions and by the use of surfactants. These compositions 
can also contain adjuvants such as preservatives, wetting 
agents, emulsifying agents and dispersing agents. Prevention 
of the action of microorganisms can be ensured by the inclu-
55 sian of various antibacterial and antifungal agents such as 
paraben, chlorobutanol, phenol, sorbic acid and the like. It 
can also be desirable to include isotonic agents such as sugars, 
sodium chloride and the like. Prolonged absorption of the 
injectable pharmaceutical form can be brought about by the 
60 inclusion of agents, such as aluminum mono stearate and gela-
tin, which delay absorption. Injectable depot forms are made 
by forming microencapsule matrices of the drug in biode-
gradable polymers such as polylactide-polyglycolide, poly 
( orthoesters) and poly( anhydrides). Depending upon the ratio 
65 of drug to polymer and the nature of the particular polymer 
employed, the rate of drug release can be controlled. Depot 
injectable formulations are also prepared by entrapping the 
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drug in liposomes or microemulsions which are compatible 
with body tissues. The injectable formulations can be steril-
ized, for example, by filtration through a bacterial-retaining 
filter or by incorporating sterilizing agents in the form of 
sterile solid compositions which can be dissolved or dis-
persed in sterile water or other sterile injectable media just 
prior to use. Suitable inert carriers can include sugars such as 
lactose. 
16 
will be recognized by those or ordinary skill in the art, the 
appropriate administration aiding device will depend on the 
formulation of the compound or composition that is selected 
and/or the desired administration site. For example, if the 
formulation of the compound or composition is appropriate 
for injection in a subject, the device could be a syringe. For 
another example, if the desired administration site is cell 
culture media, the device could be a sterile pipette. 
In some embodiments a kit can comprise one of the present Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, buff-
ers, bacteriostats, bactericidal antibiotics and solutes that ren-
der the formulation isotonic with the bodily fluids of the 
intended recipient; and aqueous and non-aqueous sterile sus-
pensions, which can include suspending agents and thicken-
ing agents. 
10 compounds and/or pharmaceutical compositions thereof as 
well as a device for activating the compound or pharmaceu-
tical composition. In some embodiments the device is a light-
emitting device that emits light having at least a wavelength 
that can activate the compound or pharmaceutical composi-
The compositions can take such forms as suspensions, 
solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powder form for constitution with a suitable vehicle, 
e.g., sterile pyrogen-free water, before use. 
15 tion. Accordingly, the device can be capable of emitting light 
having at least a wavelength of 500 nm or more, and in some 
instances a wavelength in a range of about 500 nm to about 
1100 nm. In certain embodiments the device is a laser. 
Still further, the presently-disclosed subject matter 
The formulations can be presented in unit-dose or multi-
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) condi-
tion requiring only the addition of sterile liquid carrier imme-
diately prior to use. 
20 includes a method for treating cancer. In some embodiments 
the method comprises administering a compound, including 
one of the compounds described herein, to a subject in need 
thereof, and then exposing a site of the subject to light after 
the compound has been administered. As described above, the 
25 light in some embodiments can be a light having a wavelength 
of about 350 nm to about 1000 nm. 
For oral administration, the compositions can take the form 
of, for example, tablets or capsules prepared by a conven-
tional technique with pharmaceutically acceptable excipients 
such as binding agents (e.g., pregelatinized maize starch, 30 
polyvinylpyrrolidone or hydroxypropyl methylcellulose ); 
fillers (e.g., lactose, microcrystalline cellulose or calcium 
hydrogen phosphate); lubricants (e.g., magnesium stearate, 
talc or silica); disintegrants (e.g., potato starch or sodium 
starch glycollate ); or wetting agents (e.g., sodium Iaury! sui- 35 
phate ). The tablets can be coated by methods known in the art. 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid prepa- 40 
rations can be prepared by conventional techniques with 
pharmaceutically acceptable additives such as suspending 
agents (e.g., sorbitol syrup, cellulose derivatives or hydroge-
nated edible fats); emulsifying agents (e.g. lecithin or acacia); 
non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alco- 45 
hoi or fractionated vegetable oils); and preservatives (e.g., 
methyl or propyl-p-hydroxybenzoates or sorbic acid). The 
preparations can also contain buffer salts, flavoring, coloring 
and sweetening agents as appropriate. Preparations for oral 
administration can be suitably formulated to give controlled 50 
release of the active compound. For buccal administration the 
compositions can take the form of tablets or lozenges formu-
lated in conventional manner. 
The compounds can also be formulated as a preparation for 
implantation or injection. Thus, for example, the compounds 55 
can be formulated with suitable polymeric or hydrophobic 
materials (e.g., as an emulsion in an acceptable oil) or ion 
exchange resins, or as sparingly soluble derivatives (e.g., as a 
sparingly soluble salt). 
The compounds can also be formulated in rectal composi- 60 
tions (e.g., suppositories or retention enemas containing con-
ventional suppository bases such as cocoa butter or other 
glycerides), creams or lotions, or transdermal patches. 
The presently-disclosed subject matter further includes a 
kit that can include a compound/or pharmaceutical composi- 65 
tion as described herein, packaged together with a device 
useful for administration of the compound or composition. As 
The term "administering" refers to any method of provid-
ing a compound and/or pharmaceutical composition thereof 
to a subject. Such methods are well known to those skilled in 
the art and include, but are not limited to, oral administration, 
transdermal administration, administration by inhalation, 
nasal administration, topical administration, intravaginal 
administration, ophthalmic administration, intraaural admin-
istration, intracerebral administration, rectal administration, 
and parenteral administration, including injectable such as 
intravenous administration, intra-arterial administration, 
intramuscular administration, and subcutaneous administra-
tion. Administration can be continuous or intermittent. In 
various aspects, a preparation can be administered therapeu-
tically; that is, administered to treat an existing disease or 
condition (e.g., cancer, tumors, etc.). In further various 
aspects, a preparation can be administered prophylactically; 
that is, administered for prevention of a disease or condition. 
In some embodiments a subject will be administered an 
effective amount of the compound. In this respect, the term 
"effective amount" refers to an amount that is sufficient to 
achieve the desired result or to have an effect on an undesired 
condition. For example, a "therapeutically effective amount" 
refers to an amount that is sufficient to achieve the desired 
therapeutic result or to have an effect on undesired symptoms, 
but is generally insufficient to cause adverse side effects. The 
specific therapeutically effective dose level for any particular 
patient will depend upon a variety of factors including the 
disorder being treated and the severity of the disorder; the 
specific composition employed; the age, body weight, gen-
eral health, sex and diet of the patient; the time of adminis-
tration; the route of administration; the rate of excretion of the 
specific compound employed; the duration of the treatment; 
drugs used in combination or coincidental with the specific 
compound employed and like factors well known in the medi-
cal arts. For example, it is well within the skill of the art to 
start doses of a compound at levels lower than those required 
to achieve the desired therapeutic effect and to gradually 
increase the dosage until the desired effect is achieved. If 
desired, the effective daily dose can be divided into multiple 
doses for purposes of administration. Consequently, single 
dose compositions can contain such amounts or submultiples 
US 9,290,528 Bl 
17 
thereof to make up the daily dose. The dosage can be adjusted 
by the individual physician in the event of any contraindica-
tions. Dosage can vary, and can be administered in one or 
more dose administrations daily, for one or several days. 
Guidance can be found in the literature for appropriate dos-
ages for given classes of pharmaceutical products. In further 
various aspects, a preparation can be administered in a "pro-
phylactically effective amount"; that is, an amount effective 
for prevention of a disease or condition. 
Additionally, the terms "subject" or "subject in need 10 
thereof' refer to a target of administration, which optionally 
displays symptoms related to a particular disease, pathologi-
cal condition, disorder, or the like. The subject of the herein 
disclosed methods can be a vertebrate, such as a mammal, a 
fish, a bird, a reptile, or an amphibian. Thus, the subject of the 15 
herein disclosed methods can be a human, non-human pri-
mate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig 
or rodent. The term does not denote a particular age or sex. 
Thus, adult and newborn subjects, as well as fetuses, whether 
male or female, are intended to be covered. A patient refers to 20 
a subject afflicted with a disease or disorder. The term "sub-
ject" includes human and veterinary subjects. 
In some embodiments the subject in need thereof will be 
suffering or will have been diagnosed with one or more neo-
plastic or hyperproliferative diseases, disorders, pathologies, 25 
or conditions. Thus, a site to be exposed in a subject may be 
in close proximity or at the location of such a disease, condi-
tion, etc. (e.g., tumor). Examples of such diseases, conditions, 
and the like include, but are not limited to, neoplasms (can-
cers or tumors) located in the colon, abdomen, bone, breast, 30 
digestive system, esophagus, liver, pancreas, peritoneum, 
endocrine glands (adrenal, parathyroid, pituitary, testicles, 
ovaries, cervix, thymus, thyroid), eye, head and neck, nervous 
(central and peripheral), lymphatic system, pelvis, skin, soft 
tissue, spleen, thoracic areas, bladder, and urogenital system. 35 
Other cancers include follicular lymphomas, carcinomas 
with p53 mutations, and hormone-dependent tumors, includ-
ing, but not limited to colon cancer, cardiac tumors, pancre-
atic cancer, melanoma, retinoblastoma, glioblastoma, lung 
cancer, intestinal cancer, testicular cancer, stomach cancer, 40 
neuroblastoma, myxoma, myoma, lymphoma, endothelioma, 
osteoblastoma, osteoclastoma, osteosarcoma, chondrosar-
coma, adenoma, breast cancer, prostate cancer, Kaposi's sar-
coma and ovarian cancer, or metastases thereof. 
A subject may also be in need thereof because they have 45 
acquired diseases or conditions associated with abnormal and 
increased cell survival such as, but are not limited to, progres-
sion and/or metastases of malignancies and related disorders 
such as leukemia (including acute leukemias (e.g., acute lym-
phocytic leukemia, acute myelocytic leukemia, including 50 
myeloblastic, promyelocytic, myelomonocytic, monocytic, 
and erythroleukemia) and chronic leukemias (e.g., chronic 
myelocytic (granulocytic) leukemia and chronic lymphocytic 
leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's 
disease and non-Hodgkin's disease), multiple myeloma, 55 
Waldenstrom' s macroglobulinemia, heavy chain disease, and 
solid tumors including, but not limited to, sarcomas and car-
cinomas such as fibrosarcoma, myxosarcoma, liposarcoma, 
chondrosarcoma, osteogenic sarcoma, chordoma, angiosar-
coma, endotheliosarcoma, lymphangiosarcoma, lymphan- 60 
gioendotheliosarcoma, synovioma, mesothelioma, Ewing's 
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carci-
noma, pancreatic cancer, breast cancer, ovarian cancer, pros-
tate cancer, squamous cell carcinoma, basal cell carcinoma, 
adenocarcinoma, sweat gland carcinoma, sebaceous gland 65 
carcinoma, papillary carcinoma, papillary adenocarcinomas, 
cystadenocarcinoma, medullary carcinoma, bronchogenic 
18 
carcinoma, renal cell carcinoma, hepatoma, bile duct carci-
noma, choriocarcinoma, seminoma, embryonal carcinoma, 
Wilm's tumor, cervical cancer, testicular tumor, lung carci-
noma, small cell lung carcinoma, bladder carcinoma, epithe-
lial carcinoma, glioma, astrocytoma, medulloblastoma, cran-
iopharyngioma, ependymoma, pinealoma, 
hemangioblastoma, acoustic neuroma, oligodendroglioma, 
menangioma, melanoma, neuroblastoma, and retinoblas-
toma. The conditions, diseases, and the like described above, 
as well as those that will be apparent to those of ordinary skill 
in the art, are collectively referred to as "cancer" herein. 
The terms "treatment" or "treating" refer to the medical 
management of a subject with the intent to cure, ameliorate, 
stabilize, or prevent a disease, pathological condition, or dis-
order. This term includes active treatment, that is, treatment 
directed specifically toward the improvement of a disease, 
pathological condition, or disorder, and also includes causal 
treatment, that is, treatment directed toward removal of the 
cause of the associated disease, pathological condition, or 
disorder. In addition, this term includes palliative treatment, 
that is, treatment designed for the relief of symptoms rather 
than the curing of the disease, pathological condition, or 
disorder; preventative treatment, that is, treatment directed to 
minimizing or partially or completely inhibiting the develop-
ment of the associated disease, pathological condition, or 
disorder; and supportive treatment, that is, treatment 
employed to supplement another specific therapy directed 
toward the improvement of the associated disease, pathologi-
cal condition, or disorder. 
With regard to the step of exposing a site, the method of 
exposing can be modified to meet the needs of a particular 
situation. Accordingly, the light can be sunlight, photo-optic 
light, or laser light, and thus the light can be ultraviolet light, 
visible light, near infrared light, or infrared light, for example. 
The light can be exposed from a laser light source, a tungsten 
light source, a photooptic light source, and the like. Light can 
also be exposed in at relatively specific sites, and therefore 
can be exposed by the use of laser technology, fibers, probes, 
tubes, and the like. Such probes, fibers, or tubes can be 
directly inserted, for example, into a body cavity or opening 
of a subject, or under or through the skin of a subject, to 
expose the compounds that have been administered to light. 
It will be appreciated that embodiments of the presently-
disclosed subject matter resolve the unmet needs in the art, 
including specific embodiments of strained Ru(II) polypy-
ridyl complexes that utilize the steric clash of their ligands to 
promote visible light mediated ligand expulsion. While unre-
active in the dark, these exemplary compounds are trans-
formed upon light activation into potent cytotoxic species. As 
potential PDT agents, these compounds offer key advantages, 
including ease of synthesis, high solubility, low dark toxici-
ties, and resistance to inactivation by thiol reagents. In certain 
embodiments, the DNA damaging mechanism appears to 
mimic the activity of cisplatin, which would make them 
potentially amenable to a variety of cancer types, and also can 
have greater potency than cisplatin. 
EXAMPLE 
The presently-disclosed subject matter is further illustrated 
by the following specific but non-limiting example. The 
example may include compilations of data that are represen-
tative of data gathered at various times during the course of 
development and experimentation related to the presently-
disclosed subject matter. 
Example 1 
In this Example two heteroleptic complexes were synthe-
sized containing one and two biquinoline (biq) ligands, and 
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one or two smaller, non -strained 1, 10-phenanthroline (ph en) 
ligands, as shown in FIG. 1. The synthesis and purification 
was performed under low ambient light in order to avoid 
photo-decomposition. The addition of the biq ligands resulted 
in bathochromic shifts in the absorption spectra, as compared 
to Ru(phen)3 , a prototypical Ru(II) polypyridyl complex with 
a "-max =450 nm for the low energy MLCT absorption. As 
shown in FIG. 1, addition of one biquinoline ligand in 1 shifts 
the MLCT to lower energies, with "-max =525 nm. Incorpora-
tion of two biquinoline ligands further shifts the "-max to 550 10 
nm for 2. Expansion of the region from 600-900 nm shows 
that there is some absorption at 700 nm for 1, while 2 is able 
to absorb light up to goo nm. 
Analysis of the crystal structures for the biquinoline com-
plexes provided a means to compare the extent of distortion in 15 
the ground state structures. The deformation of the octahedral 
geometry was manifest in lengthening of the bonds between 
the metal and the ligand as well as twisting of the ligands 
(FIG. 2). In comparison with Ru(phen)3 , an undistorted octa-
hedral complex with average Ru-N bond lengths of2.064 A, 20 
compound 2 was slightly distorted with the Ru-N bonds 
lengthened to 2.0g-2.10A, as shown in FIG. 2 and Table 1. In 
compound 1, one of the phenanthroline ligands maintains an 
average length similar to that ofRu(phen)3 at about 2.060 A, 
while the other two ligands' Ru-N bonds are lengthened to 25 
an average of 2.11 and 2.09 A. The biquinoline in 1 was 
twisted by 5° about the C-C bond between the two quinoline 
systems. In contrast, the two biquinoline ligands showed dif-
ferent distortions in compound 2, with biq(2) exhibiting a 
12.1(4°) twist, while biq(1) has a 2.7(4°) rotation. The 30 
biquinolines are also bent out of the normal plane by appro xi-
mately 20° in both complexes, while the phenanthroline 
ligands stay in the plane. This bend out of plane tips the 
biquinoline toward the phenanthroline ligand for 2, creating a 
20 
well with the absorption spectra, with rapid reaction observed 
with blue and green light, while slower ejection kinetics 
occurred with red and near-IR light. The most rapid ejection 
was observed with blue light for complex 2, as shown in FIG. 
3, with a t112 of 53 seconds.A t112 ofg.7 minutes was measured 
for 1. 
The presence of isosbestic points in the absorption spectra 
indicated the direct conversion from starting material to a 
single product. Samples of each complex after light activation 
were subjected to analytical HPLC. The tris-polypyridyl 
compounds are converted to bis-polypyridyl complexes with 
the selective ejection of a biquinoline ligand in all cases, as 
indicated by the peak with a retention time of32.1 minutes 
(identified as the free biquinoline ligand). The phenanthroline 
ligand was not observed in any of the chromatograms, and the 
only free ligand that was detected in the mass spectra for all 
samples was biquinoline. Without being bound by theory, the 
selective labilization of the biquinoline indicates that the dis-
tortion due to the twisting of the ligand may drive the ejection 
process, the breaking of the Ru-ligand bonds proceeds 
through a step-wise mechanism, and fused ring systems such 
as phenanthroline may re-coordinate the metal, preventing 
ligand loss. The quinoline rings in the biquionline ligand can 
rotate about the C2 -C2 • bond, inhibiting re-coordination. 
The ability of the ruthenium complexes to damage DNA 
upon light activation was determined by gel electrophoresis 
with supercoiled pUC19 plasmid, as shown in FIG. 4. All 
complexes induced a dose-dependent effect on the DNA 
mobility, with increasing retention indicating photobinding 
of the complex to the plasmid DNA. The decreased migration 
on the gel with increasing concentration of complex is con-
sistent with a DNA crosslinking effect. It should be noted that 
intercalation also causes decreased migration in agarose gels, 
but as the effect was not observed for 1 and 2 in the absence 
7° increase in the angle between the biquinoline ligands, as 
well as an go and 10° compression in the biquinoline-phenan-
throline angle. In contrast, the biquinoline ligand in com-
pound 1 pushes the two phenanthroline ligands toward each 
other by go. In both structures the biquinoline ligands maxi-
mize the space around them, which induces the distortion in 
complexes 1 and 2. 
35 of light, intercalation of the compounds is unlikely. Similar 
results were obtained for Ru(phen )2 (H2 0 )2 , which covalently 
modifies DNA. 
TABLE 1 
The compounds did not appear to photocleave DNA, as no 
increase in the linear or relaxed circle forms of DNA 
40 were observed. A significant loss of the ethidium bromide 
(EtBr) signal was observed for the light activated 1, 2, and 
Selected bond lengtbs (A). bond angles (c). and torsion angles (c) for compounds 1 and 2. 
Compound 1 
Ru-Nl-biq 
Ru-N2-biq 
Ru-N3-phen(l) 
Ru-N4-phen(l) 
Ru-N S-phen(2) 
Ru-N6-phen(2) 
2.112(3) 
2.095(3) 
2.063(3) 
2.056(3) 
2.091(3) 
2.091(3) 
Compound 2 
Ru-Nl-biq(l) 
Ru-N2-biq(l) 
Ru-N3-biq(2) 
Ru-N4-biq(2) 
Ru-NS-phen 
Ru-N6-phen 
2.084(2) 
2.079(2) 
2.088(2) 
2.093(2) 
2.104(3) 
2.098(2) 
N2-biq-Ru-N3-phen(l) 
N4-phen(l)-Ru-NS-phen(2) 
N 1-biq -Ru-N2-biq ----C 10-biq 
N 1-biq ----C9-biq ----C 10-biq -N2-biq 
99.15(12) 
82.75(12) 
-20.72(4) 
N2-biq(l)-Ru-N3-biq(2) 
N4-biq(2)-Ru-N 5-phen 
97.14(10) 
80.14(9) 
-20.41(19) 
2.7(4) 
-19.5(2) 
12.1(4) 
-5.62(5) 
N l-biq(l)-Ru-N2-biq(l)----C 10-biq(l) 
N l-biq(l)----C9-biq(l)----C lO-biq(l)-N2-biq(l) 
N 4-biq(2) -Ru-N 3-biq(2)----C27 -biq(2) 
N 3-biq(2)----C27 -biq(2)----C28-biq(2)-N4-biq(2) 
The complexes all underwent photo-substitution reactions 
upon exposure to visible light. The kinetics of the ejection 
process were followed by absorption spectroscopy, as shown 
in FIG. 3. The number of sterically hindered ligands and the 
corresponding distortion in the complex affected the rate of 
the photosubstitution reaction, with an order of magnitude 
variation in t112 for the different structures. The wavelength 
dependence of the photochemical process also correlated 
60 
Ru(phen)2 (H20)2 at concentrations above 15 f.LM. To deter-
mine if this signal loss was due to degradation of the DNA, 
bands were excised, purified and quantified for DNA content. 
Approximately go% of the plasmid was recovered from the 
excised bands, despite a 9g% reduction of the EtBr signal. 
65 Without being bound by theory, this suggests that the ruthe-
nium interferes with the EtBr emission and/or the structure of 
the ruthenium modified DNA prevents intercalation. The 
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purified DNA exhibited the same decreased mobility pattern 
when subjected to a second agarose gel, supporting a cova-
lent, photo binding mechanism for I and 2. This may provide 
an advantage over DNA photocleavage mediated by PDT 
agents and other metal complexes that require oxygen and 5 
generate single strand breaks, which may be readily repaired. 
The photoreactivity of I and 2 was dependent on the wave-
length of light used. Significant activity was retained upon 
shifting to both red and near-IR light, as indicated by gel shift. 
It should be noted, however, that the light intensity is signifi- 10 
cantly attenuated by the longer wavelength cut-off filters 
(e.g., >600 nm). There is also diminished molar absorptivity 
for the compounds in the red and near-IR region. Thus, more 
intense red or near-IR light sources likely would increase the 
apparent potency of the compounds. This is supported by the 15 
fact that irradiation for longer times induced greater DNA 
photobinding. Both complexes showed negligible reactivity 
with the DNA in the dark. 
22 
flash chromatography, and converted to chloride salts for 
testing. 
Materials and General Methods 
All chemicals for this Example were obtained from com-
mercial sources and were used without further purification. 
Ru(bpy)2 Cl2 .2H20 was purchased from Strem Chemicals 
Inc. (Newburyport, Mass.) and 5-aminolevulinic acid hydro-
chloride (ALA) was purchased from Alfa Aesar (Ward Hill, 
Mass.). 
All 1 H NMR were obtained on a Varian Mercury spectrom-
eter ( 400 MHz; Palo Alto, Calif.) and chemical shifts reported 
relative to the residual solvent peak of acetonitrile at o 1.93. 
The 13C chemical shifts are reported relative to CD3 CN at o 
1.39. Electrospray ionization (ESI) mass spectra were 
obtained on a Varian 1200L mass spectrometer. Absorption 
spectra were obtained on an Agilent S453 Diode Array spec-
trophotometer (Santa Clara, Calif.). Photoexpulsion experi-Cytotoxicity studies were performed to determine if the 
light-induced DNA damage translated to biological activity 20 ments were performed using a Dell200 Watt 141 OX projector 
(for in vitro photoejection experiments) or 410 Watt 955 
Model 900 AJH projector (for cell cytotoxicity studies) (Dell 
Inc.; Round Rock, Tex.) fitted with an Edmund Optics filter 
(NT43-935) (Barrington, N.J.). UV/Vis experiments were 
in cancer cells. The complexes exhibited dose dependent 
cytotoxicity in the HL-60 human leukemia cell line. The 
activity of the compounds was also dependent on the light 
dose, indicating that light-activation is correlated with cyto-
toxicity. The compounds were incubated with the cells for 12 
hours prior to irradiation with blue (>400 nm), red (>600 nm), 
and near-IR (>650 nm) light (Table 2). This potency is com-
parable to cisplatin, which was found to have an IC50 value of 
3.1 f.LM. Increasing the light dose increased the observed 
potency. For example, compound 2 showed a 2-fold enhance- 30 
ment in potency upon increasing the irradiation time from 3 to 
25 performed in a 1-cm pathlength quartz cuvette located IS 
inches from the projector. Kinetics were fit using the equation 
for a single exponential with the Prism software package. Cell 
survival was quantified using a Tecan Spectroflur Plus Micro-
plate Reader (Tecan Systems, Inc.; San Jose, Calif.). 
6 minutes with red light, recovering the activity measured 
under irradiation with blue light. The superior activity of 2 
compared to I with red and near-IR light irradiation is con-
sistent with the presence of a longer wavelength absorption 35 
feature extending past 700 nm. A phototoxicity index (PI) 
value (the toxicity in the dark vs. the light) of 43 was found 
with blue light for compound I. Compound 2 was more 
potent than I with red- and near-IR light, exhibiting a PI of20 
and 9.2, respectively. 
TABLE2 
Photobiological activity in HL-60 cells. 
Com- A.ab/nm IC 
pound (E/M- 1cm-1) Dark Blue (3 min) Red (3 min) Red (6min) 
525 (8,300) 52.5 1.22 13.8 7.63 
2 550 (4,950) 47.3 2.4 4.54 2.29 
Cisplatin 3.1 3.1 N.D. N.D. 
Example 2 
In this Example three complexes with structural differ- 55 
ences were explored to test the strain-mediated photoactiva-
tion approach (Table 3 ). The complexes were synthesized and 
characterized as a racemic mixture of A and A enantiomers. 
Ru(bpy )2phen (3) was used as an unstrained control. In order 
to distort the geometry about the octahedral metal center, 60 
polypyridylligands with methyl substituents were incorpo-
rated into the Ru(II) complexes; these groups are directed 
towards the other coordinating ligands, causing steric clashes. 
The complexes were readily prepared under low light condi- 65 
tions by refluxing the precursor Ru(bpy )2 Cl2 with the desired 
ligand in ethylene glycol. They were purified by silica gel 
Furthermore, chloride salts of the ruthenium complexes 
were injected on anAgilent II 00 Series HPLC equipped with 
a model GI311A quaternary pump, GI315B UV diode array 
detector and Chemstation software version B.01.03. Chro-
matographic conditions were optimized on a Colunm Tech-
nologies Inc. CIS, 120 A (250 mmx4.6 mm iuner diameter, 5 
f.tm) (Downers Grove, Ill.) fitted with a Phenomenex CIS (4 
mmx3 mm) (Torrance, Calif.) guard colunm. 15 f.LL injection 
volumes of 30 f.LM solutions of the complex were used. The 
detection wavelength was 2SO nm. Mobile phases used were 
0.1% formic acid in dH2 0 and 0.1% formic acid in HPLC 
Phototoxicity Index (PI) 
IR(25min) Blue IR 
15.8 43 3.32 
5.14 19.7 9.2 
N.D. N.D. 
grade acetonitrile (Fisher Brand; Pittsburgh, Pa.). The gradi-
ent is shown in the table below. 
Time (minutes) 0.1% formic acid in dH2 0 
0 98 
2 95 
70 
15 70 
20 40 
30 
35 98 
40 98 
0.1% formic acid in MeCN 
2 
30 
30 
60 
95 
2 
2 
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All metal complexes were synthesized and handled in low f.tg/ml of plasmid was incubated with compound dosed from 
ambient light. The metal complexes were converted to the 0 to 500 f.LM in 96 well plates. They were incubated for 30 min 
chloride salts prior to biological testing to increase water prior to light activation for 1 hour using a Dell 141 Ox 200 W 
solubility. The ion exchange was accomplished by precipita- projector fitted with a >450 nm cut-off filter. Dark controls 
tion of the complex from dry acetone by the addition of 5 were performed by keeping the DNA: compound mixtures in 
tetrabutylammonium chloride. The compounds were filtered the dark. The samples were incubated overnight after light 
and stored in the dark. The synthesis of the 2,9-dimethyl dpq activation before gel analysis; the dark samples were also 
ligand was performed according to known procedures. incubated for the same time period. Linear plasmid and 
Compound 4: Ru(bpy)2Cl2 .2H2 0 (200 mg, 0.384 mmol) relaxed circle plasmid were generated and run side-by-side 
and 6,6'-dimethyl-2,2'-bipyridine (78 mg, 0.423 mmol) were 10 with compound treated samples. Linear plasmid was gener-
added to 8 mL of degassed ethylene glycol in a pressure tube. ated using the EcoRI restriction enzyme (New England 
The mixture was heated in the dark for 6 hours, allowed to BioLabs; Ipswich, Mass.) following the manufacturers pro-
cool and poured into 50 mL of distilled water. Addition of a tocol. Single cut, relaxed circle, plasmid was generated using 
saturated aq. KPF 6 solution produced a dark orange precipi- the copper phenanthroline reaction. Reaction was carried out 
tate that was collected by vacuum filtration. The purification 15 in 10 mM phosphate buffer pH 7 .5, with 40 flg/ml plasmid, 1 
of the solid was carried out by flash chromatography (silica mM DTT, 1 mM hydrogen peroxide, and 5 f.LM copper 
gel, 0.1% saturated KN03 , 2% H2 0 in MeCN ramped to 9% phenanthroline for 30 min at 25° C. The addition of DTT 
H2 0) to give the pure complex. A saturated aq. solution of reduced the copper phenanthroline to the +1 charge state, 
KPF 6 was added, and the metal complex was extracted into followed by reaction with peroxide created the damage to the 
CH2 Cl2 . It was dried down to give a red solid. Yield: 297 mg 20 DNA. Samples were resolved on a 1% non-EB (ethidium 
(87% ). bromide) agarose gel followed by 40 minutes of staining with 
Compound 5: Ru(bpy)2Cl2 .2H2 0 (200 mg, 0.384 mmol) 0.5 flg/ml EB in Tris-Acetate buffer followed by 40 minutes 
and 2,9-dimethyldpq (150 mg, 0.577 mmol) were added to 8 of destaining in Tris-Acetate before imaging. 
mL of degassed ethylene glycol in a 15 mL pressure tube. The Glutatione Assay: 
mixture was heated with stirring in the dark for 6 hours. The 25 The pUC19 plasmid was incubated at 25 f.tg/ml with 30 
dark red solution was allowed to cool and poured into 50 mL mM of either compound 4 or cisplatin nitrate in 10 mM 
of distilled water. Addition of a saturated aq. KPF 6 solution phosphate buffer pH 7 .5, with increasing amounts of gin-
produced a dark orange precipitate that was collected by tathione (GSH) at 25° C. Cisplatin (30 f.LM) and compound 4 
vacuum filtration. The purification of the solid was carried out (30 f.LM) were co-dosed with increasing concentrations of 
by flash chromatography (silica gel, 0.1% saturated KN03 , 30 GSH. The concentrations of GSH were 0.01, 0.1, 1, 10, 40 
2% H20 in MeCN ramped to 9% H2 0) to give the pure mM, giving a molar ratio between the compounds and glu-
complex.A saturatedaq. solutionofKPF 6 was added, and the tathione of a) 1:0.3, b) 1 :3.3, c) 1:33, d) 1:333, e) 1:1333. 
metal complex was extracted into CH2 Cl2 . It was dried down Compound 4 was activated with light for 1 hr as described 
to give a red solid. Yield: 284 mg (77%). above followed by a 12 hr incubation in the dark, while 
Compound 6: Ru(bpy)2phen. 35 cisplatin nitrate was incubated with plasmid and GSH in the 
Photoejection dark for 12 hrs. Control reactions with pUC19 in the presence 
It was observed that addition of the methyl groups to either and absence of GSH were carried out for 12 hrs in the dark 
bpy (2,2'-bipyridyl) or the DNA intercalating ligand dpq with 25 flg/ml plasmid and 40 mM GSH in 10 mM phosphate 
( dipyrido[3,2-f:2',3'-h]-quinoxaline) results in complexes buffer, pH 7 .5. The plasmid was resolved on a 1% agarose gel 
that undergo photochemical reactions upon exposure to light. 40 as described above. 
Irradiation of 4 and 5 in either acetonitrile or buffer with >450 The results of the gel electrophoresis are shown in FIG. 6. 
nmlightusinga200Wprojectorandcut-offfiltersresultedin Cisplatin kinked DNA and caused unwinding, reducing its 
substitution of solvent molecules for the polypyridylligand. mobility on agarose gels and impeding intercalation ofEtBr. 
The photochemical reaction was conveniently followed by Cu(phen)2 produced single strand breaks, generating relaxed 
UV/Vis absorption spectroscopy, as shown in FIG. 5. 45 circular plasmid DNA. Exposure of ruthenium compounds 
The photo-ejection is both rapid and selective, with a t 112 of 3-5 to visible light (200 W, 1 hour) in the presence of pUC19 
2 minutes for 4 and clear isosbestic points at 351, 389, and plasmid produced both effects: DNA photocleavage (in the 
476 nm, highlighting the selectivity of the photo-labilization. case of compound 3), and DNA photo binding, which may be 
ESI-MS experiments identified the ejection of the 6,6'-dim- crosslinking (in the case of 4). Compound 5 exhibited a com-
ethyl-2,2'-bpy ligand from compound 4, while compound 5 50 bination of these two mechanisms. Light-induced DNA 
ejects the 2,9-dimethyl-dpq ligand. The reaction went to single strand breaks produced by 3 are shown as the conver-
completion for 4. The reaction kinetics are 30-fold faster for sian of supercoiled DNA to relaxed circular form (FIG. 6A). 
4 than for 5, possibly due to the rigidity of the dpq ligand that DNA photo binding for 4 and 5 is evidenced by the super-
may enhance re-chelation, interfering with the stepwise dis- coiled DNA that migrated more slowly through the gel and 
sociative bond breaking mechanism that releases the ligand. 55 EtBr intercalation was diminished with increasing concentra-
Control compound 3 was photo-stable under the irradiation tion of the Ru(II) complexes (FIGS. 6B and 6C). An addi-
conditions used. All complexes were stable the dark in aque- tiona! form was observed with high concentrations of 5 that 
ous solution at concentrations of 50 mM for months at room migrated more quickly that the relaxed circular form (FIG. 6C 
temperature. 
Biological Procedures 
lanes 8-10). Without light no DNA damage or binding was 
60 observed. 
Plasmid-compound gel analysis: Plasmid pUC19 was 
obtained from Bio-Rad (Hercules, Calif.), transformed into 
DH5a cells and positive transformants were selected by 
colony formation on Ampicillin LB-Agar plates. Colonies 
were grown in LB and plasmid isolated using a Maxi-prep 65 
plasmid isolation kit (Qiagen; Velno, Netherlands). Plasmid 
amounts were quantified by UVNIS. For dosing studies, 40 
Unlike known agents, such as cisplatin, prodrug com-
pounds 4 and 5 did not interact with GSH over a period of 
days, as observed by UV/Vis spectroscopy. The photoacti-
vated DNA crosslinking Ru(bpy)2 species retained its ability 
to damage DNA, even at higherGSH concentrations. FIG. 6D 
shows the crosslinking of plasmid DNA by cisplatin and 
light-activated compound 4 in the presence of increasing 
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amounts of GSH. Cisplatin exhibited reduced crosslinking 
efficacy with increasing levels of GSH, as indicated by 
greater mobility of the DNA on the agarose gel. The active 
form of 4 caused greater DNA binding than cisplatin. As 
described below, cisplatin or compound 4 were co-dosed with 
increasing concentrations ofGSH. GSH reduced cytotoxicity 
for cisplatin, but not for compound 4. 
TABLE3 
26 
irradiation. In contrast, photoreactive compounds 4 and 5 
showed light-triggered toxicity. After irradiation, both com-
pounds 4 and 5 produced single f.LM IC50 values (Table 3 ). The 
complexes were more potent than cisplatin when light acti-
vated and non-toxic in the dark, with dark IC50 values over 
100 f.LM for 5 and no dark toxicity observed up to a concen-
tration of300 f.LM for 4. 
Cytotoxicity IC50 values in 2D and 3D cellular assays. The 
phototoxicity index (PI) is the ratio of the dark and light IC50 values. The 
multicellular resistance (MCR) index is the ratio of the spheroid and monolayer 
culture IC values. 
Photo-
Lig!!t IC 50 [uM] Dark IC50 [l!M] toxicity 
Com- A549 A549 Index Pib MCR 
pound HL60 A549 spheroid HL60 A549 spheroid HL60 A549 Indexc 
Cisplatin 3.1(+0.2) 3.4(0.6) n.dd 3.1(+0.1) 3.5(+0.6) 42(+3.6) 12.4 
3 81(+1.9) 40(+4) >300 240(+9) 250(+5) >300 6.3 >7.5 
4 1.6(+0.2) 1.1(+0.3) 21.3(+2.3) >300 150(+7) >300 >188 136 19.4 
2.6(+1.0) 1.2(+0.1) 64.6(+4.7) 108(+1.9) 250(+5) >300 216 208 54 
ALA 16.2(+3.2) 21(+3.5) >300 >300 87.8(+5.5) >300 >18 4.2 >14 
n.d. =not determined; see Dark IC50 value. 
Cell Survival Assay: 
35 
The light activated Ru(II) complexes caused near or com-
plete cell death, which can be a challenge with light activated 
cytotoxic systems. 
In Vivo Glutathione Assay: 
A549 cells were plated in Optimem supplemented with 1% 
serum supreme and penicillin/streptomycin in 96 well plates 
as described above. The cells were allowed to adhere to the 
plate for 12 hours and then were dosed with glutathione from 
0 to 16 mM, followed immediately by either cisplatin at the 
IC100 or compound 4 at the IC80 concentration. The IC80 was 
chosen for compound 4 since glutathione did not show a 
cytoprotective effect in previous experiments with 4. Com-
The HL60 promyelocytic leukemia cell line was obtained 
fromATCC and cultured in IMDM media (Invitrogen; Carls-
bad, Calif.) supplemented with 10% serum supreme (Lanza; 30 
Basel, Switzerland) and penicillin/streptomycin at 37° C. 
with 5% C02 . TheA549 cell line was donated and cultured in 
DMEM supplemented with glutamax, 10% serum supreme, 
and penicillin/streptomycin at 37° C. with 5% C02 . Cells 
were plated in Optimem (Life Technologies; Carlsbad, Calif.) 
supplemented with 1% serum supreme and penicillin/strep-
tomycin at 30,000 cells per well in Costar 96 well flat bottom 
clear tissue culture treated plates for HL60 and 1500 cells/ 
well for A549. The compounds were dosed from 0 to 300 f.LM, 
incubated with the cells for 12 hours, and then activated for 3 
minutes with light using a 410 W projector fitted with a >450 
nm cut-off filter. The cells were then incubated for 72 hours 
followed by the addition of Cell Titer Glo (Promega; Madi-
son, Wis.) to determine viability. Dark controls were run in 
parallel. The resulting luminescence was measured using the 
SpectraFluor Plus Plate Reader (Tecan). Data were fit to an 
equation for a sigmoidal dose response using the equation 
below, where y, and yfare the initial and final signal intensi-
ties. 
40 pound 4 was activated with 3 min a flight as described above, 
and cytotoxicity measured 72 hours after compound activa-
tion and at the same time point for the dark samples. Cellular 
viability was determined by measuring ATP concentration 
with Cell Titer Glo (Promega). Data were fit to an equation for 
45 sigmoidal dose response shown above using the Prism soft-
ware package. 
Tumor Spheroid Procedures: 
A549 cells were seeded at 2,500 cells/well in 1.5% agarose 
coated 96-well plates. After 7 days the spheroids were dosed 
50 with compounds and incubated for 12 hrs. Following this, 
they were activated by light for 3 minutes using a 410 W 
projector fitted with a >450 nm cut-off filter, or kept in the 
dark. Cellular viability was determined 72 hours after light 
activation for the irradiated samples and at the same time 
y;- YJ 
Y = Yi + 1 + 1 Q(logEc50 x)Hillslope 
Cell cytotoxicity studies were performed in HL60 leuke-
mia cells andA549lung cancer cells (see FIG. 7 and Table 3). 
Cells were incubated with compounds for 12 hours in the dark 
before irradiated with >450 nm light ( 410 W) for 3 minutes. 
Dark controls were run in parallel. Cell survival was quanti-
fied 72 hours later through the use of anATP luciferase assay, 
and confirmed by Trypan Blue staining and manual counting. 
Cisplatin exhibited the same activity under light and dark 
conditions. Control compound 1, which causes single strand 
DNA breaks, exhibited only slightly enhanced activity upon 
55 point for the dark samples by measuring ATP concentration 
with Cell Titer Glo (Promega). Data were fit to an equation for 
sigmoidal dose response shown above using the Prism soft-
ware package. 
3D tumor spheroids were used to test the compounds. 
60 Spheroids provide a system that approximates the complexity 
of in vivo tumors. These spheroids mimic the pathophysiol-
ogy of tumors, including hypoxic/necrotic regions, changes 
in cell shape, high proportions of quiescent cells, alterations 
in gene expression profiles, and diminished permeability to 
65 drugs. Spheroids exhibited the phenomena of multicellular 
resistance (MCR), similar to the diminished efficacy of che-
motherapeutics in vivo. To characterize the light-activated 
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ruthenium compounds under more challenging and biologi-
cally relevant conditions, efficacy was assessed in a 3D tumor 
model by forming tumor spheroids with A549 cells. 
Spheroids of about 600 f.tm in diameter were dosed with 
compounds and then either kept in the dark or irradiated with 5 
>450 nm light for 3 minutes. Significant light-selective cytox-
icity was observed for 4, with an IC50 value of 21 f.LM, while 
no cell death was observed up to 300 f.LM in the absence of 
light. Under the same conditions, the IC50 for cisplatin fell to 
42 f.LM in the spheroid model, and the PDT drug ALA (ami- 10 
nolevulinic acid) had no effect. The activity of 5 was lower 
than 4 in the spheroid, with a light-activated IC50 of 64 f.LM. 
Thus, the compounds exhibited twice the potency of cis-
platin in both monolayer and tumor spheroids. The MCR 
index value is low for 4, similar to cisplatin (Table 3), which 15 
has a MCR lower than that of many other chemotherapeutics. 
Example 3 
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(50 mL). Purification of the solid was carried out by flash 
chromatography on Si02 . Elution with saturated aq. KN03 / 
H2 0/CH3CN (5/15/80) gave the pure complex. After column 
purification the complex as the N03 - salt was dissolved in a 
minimal volume of water, and a saturated aq. solution of 
KPF 6 was added. The complex was extracted into CH2 Cl2 and 
the solvent removed under reduced pressure to give a deep red 
solid. Thus, the light-switch Ru(bpy)2 dppz (7) was trans-
formed into a complex 8 probe that combines DNA sensing 
with ligand ejection photochemistry, as shown in FIG. 9, by 
strain-inducing methyl groups incorporated at the 3 and 6 
positions of the dppz ligand (3,6-dimethyl dipyridylphena-
zine, dmdppz). 
Compounds 7 and 8 were converted to the cl- salt prior to 
procedures. The PF 6- salt of each complex was dissolved in a 
minimal volume of acetone (1-2 mL), followed by the addi-
tion of a solution oft-butyl ammonium chloride (1 g dissolved 
in 5 mL of acetone) producing a precipitate that was filtered 
through glass wool, washed with acetone (50 mL) and eluted 
20 with acetonitrile. The solvent was removed under reduced This Example describes a novel ruthenium complex con-
taining a dppz derivative that undergoes photochemical 
ligand substitution reactions in the presence of DNA. The 
compound exhibited selective photochemistry to generate a 
ligand-deficient and reactive metal center, along with a free 
coordinating ligand, in the presence of nucleic acids and 25 
organic solvents. The compound was sensitive to the DNA 
tertiary structure, displaying different reactivities in duplex 
and G-quadruplex DNA, providing a mechanism for the 
development of DNA structure-selective probes and effec-
tors. 
pressure to give the pure complex. 
To perform crystallography, all crystal manipulations 
requiring exposure to light were conducted as rapidly as 
possible. To this end, the crystal( s) were plunged directly into 
liquid nitrogen and mounted using cryo-tongs. Single crystals 
of compounds 7 and 8 were grown by slow evaporation of 
methylene chloride in diethyl ether, mounted in inert oil and 
transferred to the cold gas stream of the diffractometer. X -ray 
diffraction data were collected at 90.0(2) K on a Bruker-
Chemicals used for synthesis were purchased from suppli-
30 Nonius X8 Proteum diffractometer with graded-multilayer 
focused CuK(a) x-rays. Raw data were integrated, scaled, 
merged and corrected for Lorentz-polarization effects using 
theAPEX2 package. Corrections for absorption were applied 
ers and used without further purification. Calf thymus (CT) 
DNA was purchased from Sigma-Aldrich, re-suspended in 
buffer (50 mM NaCl, 5 mM Tris buffer, pH 7 .0) and sonicated 
(bath sonicator for 40 min followed by 10-15 1 sec pulses 35 
with a Branson Sonifier 250 (duty cycle=90% and output 
control=2; Danbury, Conn.) to provide shorter strands. The 
15-mer oligonucleotide A was purchased from Integrated 
DNA Technologies (Coralville, Iowa) and the G-quadruplex 
sequence was purchased from Eurofins Scientific (Luxem- 40 
bourg), re-suspended, and annealed prior to use. The forward 
sequence for the 15-mer oligonucleotide A is 5'-CCT-CTC-
TGG-TTC-TTC-3' and the reverse sequence is 5'-GAA-
GAA-CCA-GAG-AGG-3'. The 15-mer oligonucleotide was 
re-suspended in dH20 and annealed by heating at 90° C. for 45 
5 min then cooling slowly to ambient temperature and stored 
at -20° C. The G-quadruplex sequence is 5'-[AGGG 
(TTAGGG)3]-3'. The G-quadruplex was re-suspended in 
buffer (10 mM potassium phosphate, 100 mM KCl, pH 7.0) 
and annealed by heating at 90° C. for 5 min then cooling 50 
slowly to ambient temperature, followed by incubation at 4° 
C. overnight, as previously reported. 1 
Briefly, dipyrido[3.2-a:2',3'-c]phenazine (dppz) and 
Ru(bpy )2 dppz (7) were prepared by known methods. To pre-
pare 3,6-Dimethyl-dipyrido[3,2-a:2',3'-c ]phenazine ( dmd- 55 
ppz), dimethyl-dipyrido[3,2-a:2',3'-c ]phenazine was first 
prepared by known methods modified to start with 2,9-dim-
ethylphendione. Next, to prepare Ru(bpy)2dmdppz (8), 
Ru(bpy)2 Cl2 .2H2 0 (501 mg, 0.963 mmol) and 3,6-dimethyl-
dipyrido[3,2-a:2',3'-c]phenazine (328 mg, 1.057 mmol) were 60 
added to 16 mL of degassed ethylene glycol in a 38 mL 
pressure tube. The mixture was heated at 150° C. with stirring 
and protected from light. After 16 hours the red solution was 
cooled to room temperature and poured into 50 mL of dis-
tilled water. Addition of a saturated aqueous KPF 6 solution 65 
produced a deep red precipitate that was collected by vacuum 
filtration and washed with dH20 (50 mL) and diethyl ether 
using SADABS and XABS2. The structure was solved by 
direct methods (SHELXS-97) and difference Fourier 
(SHELXL-97). Refinement was carried out against F2 by 
weighted full-matrix least-squares (SHELXL-97), and 
assessed with the aid of an R-tensor. Hydrogen atoms were 
found in difference maps but subsequently placed at calcu-
lated positions and refined using a riding model. Non-hydro-
gen atoms were refined with anisotropic displacement param-
eters. Atomic scattering factors were taken from the 
International Tables for Crystallography. 
The crystal structures of racemic Ru(bpy)2 dppz (7) and 
Ru(bpy)2 dmdppz (8) confirmed that addition of the methyl 
groups induced distortion about the metal center (FIG. 10). 
The Ru-N bonds were lengthened in the strained ligand, 
with an average of 2.10 A for the Ru-N bonds in dmdppz, in 
contrast to 2.07 A for dppz. The main distortion in compound 
8 is a 15° bending of the dmdppz ligand from the normal plane 
of the octahedral complex, due to the clash of the methyl 
group with the auxiliary ligands. The bpy ligands in either 
compound did not experience significant distortions. 
Complex 8 was rather unreactive in water, exhibiting slow 
photodecomposition when exposed to visible light (A.>400 
nm; t112>8 hours), suggesting a more discerning switch that 
could exploit triggers with light. The photoreactivity was 
increased by more than an order of magnitude in the presence 
of duplex DNA oligonucleotides and calf thymus (CT) DNA, 
with t112 values of31-41 minutes, as shown in Table 4. The 
photoejection process was characterized by both a red shift in 
the absorption spectra and decreased extinction coefficient. 
Ligand ejection was selective, as indicated by the presence of 
isosbestic points in the UVNis spectra taken as a function of 
irradiation time (FIG. 9B). It appeared that only the dmdppz 
ligand was ejected, and the photoreaction led to covalent 
metalation of the DNA. 
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TABLE4 
Photophysical and photochemical properties for 7 and 8 for various 
reaction conditions. 
Experimental Half-life 
Conditions[ a] Am=(nm) (7) (minutes) (8) 
H20 >480 
D20 605 (weak) 140 ± 10 
CH2Cl2 596 0.5 ± 0.05 
DMF 638 25 ± 2 
CTDNA 619 41 ± 2 
15 mer oligonucleotide 615 31 ± 0.5 
A 
G-Quadrup lex 613 13.5 ± 1 
BSA 146 ± 8 
10 
15 
30 
beneficial to induce photoejection, but environmental factors 
may also affect other nonradiative decay processes. 
Example 4 
This Example compares the synthesis and characterization 
of exemplary Ru(II) complexes having positive and negative 
overall charges. The compounds include Ru(bathophenan-
throline )3 (9), which is hydrophobic with a high DNA binding 
affinity, and Ru(bathophenanthorlinedisulfonate )3 (1 0), 
which is hydrophilic with a high affinity for proteins. Both 
complexes are efficient singlet oxygen C02 ) generators with 
the same quantum yields for 10 2 production (<I> ,j.) and similar 
molar extinction coefficients (E). Compound 9 carries a +2 
overall charge while 10 has a -4 overall charge. 
Table 5 provides a summary of physical and photophysical 
characteristics of the two complexes. This Example shows 
that the compounds have differences in potency, cellular 
uptake, localization, and mechanism of cytotoxicity. This 
20 Example also shows that negatively and positively charged 
Ru(III) complexes can be compatible as PDT agents. 
The distortion of compound 8 did not appear to signifi-
cantly affect the DNA binding affinity, as similar K6 values of 
1x107 and3x107 M- 1 were determined for racemic mixtures 
of7 and 8 with CT DNA. Intercalation ofboth complexes was 
consistent with the reduced mobility of supercoiled plasmid 
DNA in agarose gels, and the modulation of the absorption 
spectra in the presence of DNA, characterized by hypo-
chromism of both the Jt-Jt* of the dppz ligand and the MLCT 
transitions, with maximal effect at a ratio of 2: 1 DNA base 25 
pairs to metal center. Thus, the strained complex retained 
DNA-sensing capabilities of other Ruii "light-switch" mol-
ecules and photochemical reactivity. 
30 
Alternative tertiary structures of DNA provide potential for 
greater selectivity in gene and cellular regulation than double 
stranded motifs, and G-quadruplex structures are medically 
relevant targets for cancer research and therapies. Complex 8 
was tested as a photochemical probe for the telomeric G-qua-
druplex structure using the sequence [AGGG(TTAGGG)3 ]. 
Upon binding the quadruplex, the photoejection rate for 8 35 
increased 3-fold compared to standard double helix CT DNA, 
giving a t 112 of 13.5 minutes. 
The selectivity of the probe for DNA was compared to 
protein by testing the ejection with bovine serum albumin 
40 
(BSA). There was no observable emission for 7 in the pres-
ence of BSA, and 8 appeared to photodecompose, with no 
isobestic points in the absorption spectra and a t 112 of 146 
minutes. The reactivity with a hydrophobic protein is similar 
TABLES 
Physical and Photophysical Properties of9 and 10 
Property Compound 9 Compound 10 
Charge +2 -4 
Log P 1.8 ± 0.02 -2.2 ± 0.12 
Am=(nm) 460 462 
E (M- 1 cm- 1) 29,500 29,300 
Aem(nm) 632 632 
<l>PL 0.101 0.176 
<I>,., 0.42 0.43 
DNA Damage and Cytotoxicity 
As both 9 and 10 are efficient catalysts for the light-acti-
vated generation of 10 2 (<I> ,j.=0.42, 0.42). Their DNA damag-
ing properties were assessed with p UC19 plasmid DNA using 
gel electrophoresis. Serial dilutions of the compounds (0-500 
f.LM) were mixed with 40 flg/mL pUC19 plasmid DNA in 10 
mM potassium phosphate buffer (pH 7.4) protected from 
light or irradiated with a 200 W light source for total light 
doses of 40 J/cm2 blue filtered light (>400 nm). Samples were 
then incubated for 24 hours at room temperature protected 
to the behavior in water. 
The photochemical behaviour of 8 paralleled the photo-
physical characteristics of unstrained Ruii complexes con-
taining the dppz ligand. For example, the emission intensity 
45 from light. Controls were prepared to simulate single and 
double strand DNA breaks, and the DNA samples resolved on 
agarose gels. 
of 7 and other dppz complexes as well as of 8 increased in 
nonpolar, aprotic solvents (t112>8 hrs in water, t 112=0.5 min in 50 
CH2 Cl2 ). The luminescence of Ruii dppz complexes was 
greater in D2 0 than H20; and the ejection of 8 showed a 
similar isotope effect of >3.4. 
Samples were resolved using 1% agarose gels prepared in 
tris-acetate (TA) buffer. Each lane was loaded with 0.3 flg of 
pUC19 and the samples run for 90 minutes at 100 mV. The 
gels were stained with 500 ng/mL ethidium bromide in TA 
buffer at room temperature for 40 minutes. The gels were 
subsequently washed with fresh TA buffer at room tempera-
ture for 40 min then imaged using a ChemiDoc™ MP System 
from Bio-Rad. 
Compound 9 binds strongly with DNA, and precipitation 
of the complex with the DNA was observed at concentrations 
above 31.3 f.LM both in the light and in the dark (FIG. 12A). In 
contrast, 10 is a more hydrophilic molecule, and the nega-
tively charged sulfonate functional groups were anticipated to 
cause electrostatic repulsions between the complex and the 
negatively charged backbone of the DNA. DNA precipitation 
or smearing was not observed with up to 500 f.LM of 2 (FIG. 
12B). However, when exposed to light both 9 and 10 induced 
A proposed Jablonski diagram in FIG. 11 illustrates the 
interplay between different states. The "bright" and "dark" 55 
states are in thermal equilibrium as a function of the environ-
ment, and the dissociative 3 MC state can be accessed only 
from the "bright" state. Population of the "dark" state is 
enhanced in solvents such as water, and results in alternative 
non-radiative decay pathways that reduce the yield of photo- 60 
ejection. Without being bound by theory, the data suggests 
that the complex 8 undergoes ligand ejection photochemistry 
efficiently under conditions that destabilize polar charge 
transfer states and reduce population of the "dark" state 
MLCT and it associated non-radiative decay pathways. 65 single strand DNA breaks, creating relaxed circular plasmid. 
The present ruthenium complex therefore act as a dual 
photochemical DNA sensor and metalating agent. Strain is 
However, for 10, the amount of relaxed plasmid did not 
exhibit any concentration dependence above 125 f.LM, sug-
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gesting either a reduction in <I> ,j. as the concentration of the 
complex is increased, or alternative quenching mechanisms 
that impede DNA damage. 
32 
As both compounds are capable of light-induced DNA 
damage, the cytotoxicity of 1 and 2 were evaluated in the 5 
A549 human non-small cell lung cancer, the HL60 human 
promyelocytic leukemia, and the Jurkat human T lympho-
blastoid cell lines in presence and absence of3 J/cm2 of>400 
nm light. A549 cells were grown in 75 cm2 culture flasks in 
DMEM supplemented with 10% FBS and 1% pen-strep 10 
(DMEM) at 37° C., 5% C02 . Cell media was replaced twice 
The emission of9 and 10 was measured inA549 cells using 
anApoptome microscope. The relative rates of uptake of each 
of the complexes were analyzed as a function of time, and 
both 9 and 10 were visible inside cells as early as 2 hours after 
compound addition, consistent with the flow data and the 
ICP-OES results. Images were taken at 2, 8, 18 and 24 hours, 
and intracellular levels ofboth complexes appeared to plateau 
around 8 hours. The uptake data showed good agreement 
between the three techniques and two cell lines, suggesting 
similar behavior in adherent and suspension cell lines. 
Differences in the intracellular localization of 9 and 10 
were evaluated by determining colocalization of lumines-
cence of the compound and fluorescent markers of organelles 
in A549 cells. Overlap in signals between the compounds, 
cellular nucleus, mitochondria and lysosome was measured 
over a 24 hour period. FIG. 13 shows the 8 hour time point, 
a week and cells were maintained below 70% confluence. 
HL60 cells were grown in 75 cm2 culture flasks in IMDM 
supplemented with 10% FBS and 1% pen-strep (IMDM) at 
37° C., 5% C02 . HL60 cells were diluted 1:5 once a week 15 
with IMDM to maintain a cell concentration below 2x106 
cells/mL. 
The IC50 values across the cell lines for 1 ranged from 0.62 
to 3.75 f.LM in the dark. In the presence oflight, potency was 
increased to a range of 0.075 to 0.35 f.LM, resulting in an 
averagephototoxicity index (PI=IC50 ( dark)/IC50 light) of! 0-
to 20-fold (FIG. 12, Table 5). 
The high toxicity of 9 in the absence of light is in marked 
contrast to the behavior of 2, where no toxicity was observed 
in the dark at concentrations up to 300 f.LM across all cell lines. 
Compound 10 was effective in killing cells only when irradi-
ated, with IC50 values ranging from 3.3 to 17.25 f.LM, consis-
tent with the concentrations required for in vitro DNA dam-
age. This provides for a large therapeutic window, as cell 
death was not observed for samples in the absence of irradia-
tion. 
which demonstrates that 9 and 10 have different localization 
profiles. Compound 9 substantially localized to lysosomes 
20 and the mitochondria in the absence of light, while 10 
remained primarily in the cytosol. Exposure to light did have 
some impact on compound localization, where 9 induced 
nuclear localization of the mitochondrial and lysosome mark-
ers (FIGS. 13A and 13B), suggesting that photo-induced 
25 damage mediated by 9 reduced the integrity of the nuclear 
membrane. 10 was primarily observed in lysosomes after 
irradiation, and did not co-localize with mitochondria (FIGS. 
13A and 13B). In addition, irradiation in the presence of 10 
did not result in the appearance of organelle markers in the 
30 nucleus, suggesting the nuclear membrane remained intact. 
Neither 9 nor 10 was found to associate with the cell mem-
brane or membranes of organelles. 
Mitochondrial Function and Time Dependence for Cell 
35 
Death 
Compound 9 was toxic to cells upon irradiation and 
induced cell death more rapidly than traditional DNA dam-
aging agents such as cisplatin. Upon treatment with 9 and 
irradiation, cell death was observed within 2 hours. Cell death 
was slower for the samples kept in the dark, with approxi-
mately 30% viable cells remaining at 24 hours. For com-
pound 10 70% of viable cells remained at 24 hours and 55% 
remained at 48 hours after irradiation. The disparity in the 
potencies, therapeutic windows, and rates of cell killing for 40 
the two compounds and similar ability to sensitize 10 2 sug-
gested that they were acting through different cellular mecha-
msms. 
Without being bound by theory, compound 9 localized 
within mitochondria, which may account for its toxicity in the 
absence of irradiation. To determine if the interactions of 
either 9 or 10 with the mitochondria resulted in reduced 
mitochondrial function, mitochondrial membrane potential 
was measured using tetramethylrhodamine ethyl ester 
(TMRE). TMRE is a cationic dye that accumulates in active 
motochondria as a result of the negative membrane potential 
(lnjJm). Inactive or depolarized mitochondria exhibit a Cellular Uptake and Subcellular Localization 
Both 9 and 10 were emissive, allowing for direct visual-
ization of their cellular uptake and localization. Flow cytom-
etry and fluorescence microscopy were used to provide rela-
tive uptake values, the time dependence of compound uptake, 
and information on the subcellular localization of the com-
pounds. 9 was assayed at 5 f.LM while 20 f.LM of 10 was 
assayed. Flow cytometry with HL60 cells revealed greater 
uptake of9 compared with 10 at time points of2 and 24 hours, 
with an 11.6-fold increase and 8.2-fold increase in signal 
respectively. Between the time points of 2 and 24 hours, the 
average emission of cells incubated with 9 increased by 2.8-
fold while the amount of 10 increased by 4-fold. This data was 
supported by direct quantification of the number of ruthenium 
atoms per cell using Inductively Coupled Plasma Optical 
Emission Spectroscopy (ICP-OES). The relative amount of 
compound 9 in cells versus the cell media increased appro xi-
mately 4-fold from 2 to 24 hours, from 5.6% to 22%. Less of 
compound 10 entered the cells, with a maximal percentage 
uptake of0.7% at 24 hours. This degree of uptake is compa-
rable to cisplatin dosed at the same concentration (20 f.LM, 
0.8% at 24 hours). Irradiation increased the amount of 10 
within the cells to 1.6%. Complete cell death was observed 
with 9 within 2 hours of light exposure. 
45 decreased membrane potential and TMRE does not localize 
in these organelles. Compound 9 induced rapid and complete 
depolarization of mitochondria both in the dark and upon 
irradiation (FIGS. 14A and 14B). 
Cell viability did not parallel mitochondrial potential. 
so Mitochondrial function was completely impaired at 2 hours 
post treatment with 9 in the dark, viability decreased slowly, 
with 44±6% viable cells remaining after 24 hours. In contrast, 
both mitochondrial function and cell viability fell to about 0% 
within 2 hours of irradiation. Thus, while 9 impedes mito-
55 chondrial function within 2 hours even in the absence oflight, 
irradiation induced additional damage that resulted in cell 
death along with the loss of mitochondrial function. 
Compound 10 did not significantly reduce the mitochon-
drial potential either when irradiated or in the dark over a 24 
60 hour period. Irradiation did reduce cell viability to 70±12% at 
2 hours and 59±4% after 24 hours, but this occurred without 
a significant decrease in the relative mitochondrial potential 
(FIG. 14D), indicating 10 did not act through inhibition of 
mitochondrial function. This suggests that rapid mitochon-
65 dria failure may be connected to the dark toxicity of9, and the 
lack of mitochondrial localization and inhibition be con-
nected to the limited dark toxicity of 10. 
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The disconnect between the mitochondrial potential and 
cell viability for componnd 9 in the dark may also indicate 
that disruption of mitochondrial activity does not lead to 
immediate cell death. 
Mechanism of Cell Death 
Given the different cellular localization properties and time 
profiles for cell death induced by 9 and 10, the mechanism of 
cell death was investigated. Indicators of apoptotic cell death 
(activation of PARP and caspase 3 through proteolysis) were 
determined in HL60 cells treated with either 9 or 10 (FIGS. 10 
15A and 15B). The known apoptotic inducing compounds, 
cisplatin and doxorubicin, were rnn in parallel. Compound 9 
induced the proteolytic activation of both PARP and caspase 
3 within 2 hours of irradiation and was maximal after 8 hours 
(FIG. 15). In the absence oflight, PARP and caspase 3 were 15 
observed with 9, but after 18 and 24 hours and to a lesser 
degree. In the absence of irradiation the amount of inactive 
procaspase 3 did not change. 
Exposure of 10 to light induced PARP as early as 2 hours, 
and increasing amounts of PARP were observed over the 20 
course of 24 hours (FIG. 15). The increase in the level of 
activated caspase 3 occurred on a slower time scale than 
PARP cleavage, with the protein observed at 18 and 24 hrs. 
Thus, the irradiated samples may possibly nndergo apoptosis 
that is not primarily signaled through caspase 3. Cells treated 25 
with 10 and protected from light did not display PARP or 
caspase 3 cleavage, indicating limited cytotoxicity in the 
absence of light. The level of procaspase 3 did not change 
over 24 hours. 
Since 10 showed PARP induction without significant 30 
caspase 3 activation, as compared to 9 and cisplatin or doxo-
rubicin, a mechanism of cell death through necrosis was 
explored. The generation of an alternate 55 kDa PARP frag-
ment was determined by immnnoblot as a marker for necrosis 
with 10% (v/v) ethanol used as a control that induces necro- 35 
sis. Exposure of HL60 cells to 9 produced this fragment at 
significant levels both when protected from light and when 
irradiated, consistent with necrosis. Cisplatin and doxorubi-
cin also produced this cleavage product, indicating that some 
cells had progressed into necrosis. In contrast, cells exposed 40 
to 10 both in the presence and absence of irradiation produced 
a lower level of the 55 kDa PARP fragment, similar to the 
untreated cells, suggesting necrosis was not a significant cell 
death pathway for this componnd. 
To further analyze the mechanisms of cell death induced by 45 
9 and 10, the degradation pattern of genomic DNA was inves-
tigated. DNA laddering was observed as a result of DNA 
fragmentation stemming from the execution phase of apop-
tosis. In contrast, necrotic cell death lacked this characteristic 
laddering effect, allowing differentiation between these two 50 
mechanisms. H L60 cells were exposed to the Ru(II) com-
plexes, cisplatin, and 10% ethanol, followed by genomic 
DNA isolation and resolution by gel electrophoresis. The 
apoptosis inducer, cisplatin, initiated DNA fragmentation 
resulting in a laddering pattern on the gel (FIG. 15B). This 55 
laddering was absent in the cells treated with ethanol and 
compounds 9 and 10 in the dark. However, both componnds 
9 and 10 displayed similar laddering patterns as cisplatin 
when irradiated, suggesting apoptosis is a major cell-death 
pathway for both componnds when irradiated. In contrast, 60 
given the cytotoxicity of 9 in the dark and the presence of the 
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biological activities. Compound 9, having high DNA affinity, 
localized to the mitochondria and induced rapid membrane 
depolarization and necrotic cell death. Componnd 10, with an 
overall -4 charge, was taken up into cancer cells to a sufficient 
degree to mediate light-induced cell death through an apop-
totic pathway. 
Example 5 
This Example describes additional specific embodiments 
the presently-disclosed subject matter. The structure, light 
IC50, dark IC50 , and phototoxicity index (i.e., dark IC50/light 
IC50) for each compound is given below. The methods for 
making and characterizing the componnds are based on the 
methodologies described in the previous examples. 
TABLE6 
Physical and Photophysical Properties Exemplary Compounds 
Light IC50 
Structure (fJM) 
Cisplatin 3.1 
Ru(bpy)o-6,6'dmbpy 1.5 
Ru(bpy)odmdpq 0.6 
Ru(bpy )odmphen 0.4 
Ru(bpy )odmdppz 14 
Ru(bpy)obathocuprione 3.3 
Ru(dmphen)obpy 1.2 
Ru(dmphen)obathophen 1.7 
Ru(dmphen)odpq 0.22 
Ru(dmphen)odppz 0.5 
Ru(dmphen)ophen 0.14 
Bpy = 2,2'-bipyridine 
Phen = 1,10-phenanthroline 
Dmphen = 2,9-Dimethyl-1, 1 0-phenanthroline 
6,6'-dmbpy = 6,6'-dimethyl, 2,2'-bipyridine 
dpq = dipyrido[3,2-f:2',3'-h]-quinoxaline 
dppz = dipyrido[3,2-a:2',3'-c]phenazine 
dmdpq = 2,9-dimethyl dpq 
dmdppz = 2,9-dimethyl dppz 
bathophen = bathophenanthroline 
Dark!C50 Phototoxicity 
(f!M) Index 
3.1 
300 200 
250 400 
20 
65 4.6 
27 8.18 
150 125 
4.5 2.5 
250 1,130 
150 300 
35 250 
While the following terms used herein are believed to be 
well nnderstood by one of ordinary skill in the art, definitions 
are set forth to facilitate explanation of the presently-dis-
closed subject matter. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the presently-
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently-
disclosed subject matter, representative methods, devices, 
and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a compound" includes a plurality of such com-
pounds, and so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities, properties, and so forth used in the specification and 
claims are to be understood as being modified in all instances 
by the term "about". Accordingly, unless indicated to the 
contrary, the numerical parameters set forth in this specifica-
tion and claims are approximations that can vary depending 
upon the desired properties sought to be obtained by the 
55 kDa PARP fragment, it appears that necrotic cell death is 
one pathway for 1. For componnd 10 the absence of DNA 
laddering may be a result of the lack of cytotoxicity of the 
negatively charged compound. 65 presently-disclosed subject matter. 
Thus, ligand modifications of the present complexes can 
provide componnds with divergent physical properties and 
As used herein, the term "about," when referring to a value 
or to an amount of mass, weight, time, volume, concentration 
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or percentage is meant to encompass variations of in some 
embodiments ±20%, in some embodiments ±10%, in some 
embodiments ±5%, in some embodiments ±1 %, in some 
embodiments ±0.5%, and in some embodiments ±0.1% from 
the specified amount, as such variations are appropriate to 5 
perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 10 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" is 
also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, ifl 0 and 
15 
15 are disclosed, then 11, 12, 13, and 14 are also disclosed. 
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What is claimed is: 
1. A compound of the following formula: 
+1-m 
10 
wherein: 
ligands X1 , X2 , and X3 , the same or different from one 
15 
another, are selected from bidentate nitrogen hetero-
cycles, optionally substituted with one or more of alkyl, 
aryl, amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 , 
PR4 , OR4 , halogen, S03H, alkylamino and P, wherein R 20 
is selected from H, OH, alkyl, and aryl; 
m is -6 to +6; and 
40 
each R4 is H, amine, amide, alkyl, aryl, SR4 , PR4 , 0, 
OR4 , halogen, or S03H. 
5. The compound of claim 1, wherein at least one ofX1 , X2 , 
and X3 are selected from: 
wherein 
each R1 is independently selected from H, amine, amide, 
alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, R4 
being H, alkyl, or aryl, or wherein R1 and R3 taken 
together with the carbon atoms to which they are 
bonded, form a substituted or unsubstituted ring con-
taining about 4-6 ring carbon atoms that optionally 
include one or more N; and 
each R2 is H, amine, amide, alkyl, aryl, SR4 , PR4 , 0, 
OR4 , halogen, or S03H. at least one of the ligands Xu X2 , and X3 is a strain-
inducing ligand and are released when the compound is 
exposed to light, wherein the ligands XI, X2, and X3 are 
selected from pyridyls, phenanthrolines, quinolines, 6 
membered heteroaryl rings containing one nitrogen 
atom, or a combination thereof, and are optionally fused 
6. The compound of claim 1, wherein at least one ofX1 , X2 , 
25 and X3 are selected from: 
to a 6-membered carbocyclic ring or 6 membered het-
eroaryl ring containing 1 or 2 nitrogen atoms, and are 30 
optionally substituted with one or more of alkyl, aryl, 
amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 , 
OR4 , halogen, S03 H, alkylamino and P, wherein R is 
selected from H, OH, alkyl, and aryl; or 
a pharmaceutically acceptable derivative thereof. 
2. The compound of claim 1, wherein at least one ofX1 , X2 , 
and x3 is a strain-inducing ligand having bond lengths and/or 
bond angles that deviate by 5% or more relative to the ideal 
bond lengths and/or bond angles determined by VSEPR. 
35 
3. Thecompoundofclaim1, whereinatleastoneofX1,X2 , 40 
and X3 are selected from polypyridyl. 
4. The compound of claim 1, wherein at least one ofX1 , X2 , 
and X3 are selected from: 
wherein 
45 
50 
eachR1 is independently selectedfromH, amine, amide, 
alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, R4 
being H, alkyl, or aryl, or wherein R1 and R3 taken 55 
together with the carbon atoms to which they are 
bonded, form a substituted or unsubstituted ring con-
taining about 4-6 ring carbon atoms that optionally 
include one or more N; 
each R2 is H, amine, amide, alkyl, aryl, SR4 , PR4 , 0, 60 
OR4 , halogen, or S03 H; 
each R3 is independently selected from H, amine, amide, 
alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03H, or 
wherein R3 and R4 taken together with the carbon 
atoms to which they are bonded, form a substituted or 65 
unsubstituted ring containing about 4-6 ring carbon 
atoms that optionally include one or more N; and 
p-q 
HOOC COOH 
b-d 
d-b 
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-continued 
tBu tBu, 
b-d 
10 
15 
20 
HOOC COOH 
25 
30 
35 
40 
45 
h ~CH,).NH, h ~COOH >C 
CNK\_) CN}---\_) 
0 
0 
60 
65 
H2Nn(O(H2Ch)HN 
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-continued 
0 0 
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Q f ~ 
N N 
0 0 
and 
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-continued when the at least one of Xu X2 , and X3 is 
0 0 
and 
10 n is 2 or 4. 
wherein when the at least one of Xu X2 , and X3 is 7. The compound of claim 1, wherein at least one ofX1 , X2 , 
and X3 are a methylated bidentate nitrogen heterocycle. 
8. The compound of claim 1, according to the formula: 
15 
20 
n is from 1 to 16, 
when the at least one of Xu X2 , and X3 is 
25 
30 9. The compound of claim 1, according to the formula: 
n is 5, 7, or 9; 
when the at least one of Xu X2 , and X3 is 
35 
40 
n is 2 or 4; 
when the at least one of Xu X2 , and X3 is 45 
0 
50 10. The compound of claim 1, according to the formula: 
n is 4 or 8; 55 
when the at least one of Xu X2 , and X3 is 
0 0 
60 
65 
n is 4 or 8; and 
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11. The compound of claim 1, according to the formula: 
12. The compound of claim 1, according to the formula: 
~ ~ N 
N~ 
u 
13. The compound of claim 1, according to the formula: 
14. The compound of claim 1, further comprising a target-
ing agent. 
15. The compound of claim 14, wherein the targeting agent 
selected from folate, estrogen, and erlotinib. 
16. The compound of claim 1, wherein at least one of the 
ligands is a therapeutic agent. 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
46 
17. The compound of claim 16, wherein the therapeutic 
agent is hydroxyquinoline. 
18. The compound of claim 1, wherein the light includes a 
wavelength of about 500 nm to about 1000 nm. 
19. The compound of claim 1, wherein m is less than zero. 
20. A pharmaceutical composition, comprising a com-
pound of the following formula: 
+1-m 
wherein: 
ligands X1 , X2 , and X3 , the same or different from one 
another, are selected from bidentate nitrogen hetero-
cycles, or a combination thereof and are optionally sub-
stituted with one or more of alkyl, aryl, amine, C(O), 
C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 , OR4 , halo-
gen, S03 H, alkylamino and P, wherein R is selected 
from H, OH, alkyl, and aryl; and 
m is -6 to +6; and 
at least one of the ligands Xv X2 , and X3 is a strain-
inducing ligand and are released when the compound is 
exposed to light, wherein the ligands X1, X2, andX3 are 
selected from pyridyls, phenanthrolines, quinolines, 6 
membered heteroaryl rings containing one nitrogen 
atom, or a combination thereof, and are optionally fused 
to a 6-membered carbocyclic ring or 6 membered het-
eroaryl ring containing 1 or 2 nitrogen atoms, and are 
optionally substituted with one or more of alkyl, aryl, 
amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 , 
OR4 , halogen, S03H, alkylamino and R, wherein R is 
selected from H, OH, alkyl, and aryl; or 
a pharmaceutically acceptable derivative thereof; and 
a pharmaceutically-acceptable carrier. 
21. A method of treating lung cancer or leukemia in a 
subject, comprising: 
administering an effective amount of the compound to the 
subject, the compound including the following formula: 
+1-m 
wherein: 
X1 , X2 , andX3 , the same or different from one another, are 
selected from bidentate nitrogen heterocycles, and 
m is -6 to +6; and 
at least one of the ligands Xv X2 , and X3 is a strain-
inducing ligand and are released when the compound is 
exposed to light, wherein the ligands X1, X2, andX3 are 
selected from pyridyls, phenanthrolines, quinolines, 6 
membered heteroaryl rings containing one nitrogen 
atom, or a combination thereof, and are optionally fused 
US 9,290,528 Bl 
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to a 6-membered carbocyclic ring or 6 membered het-
eroaryl ring containing 1 or 2 nitrogen atoms, and are 
optionally substituted with one or more of alkyl, aryl, 
amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 , 
OR4 , halogen, S03 H, alkylamino and P, wherein R is 5 
selected from H, OH, alkyl, and aryl; or 
a pharmaceutically acceptable derivative thereof; and 
exposing a site of the subject to light after the step of 
administering the compound. 10 
22. The method of claim 21, wherein, in the exposing step, 
the compound releases one or more ofX1 , X2 , and X3 . 
23. The method of claim 21, wherein at least one ofXu X2 , 
and X3 are polypyridyl. 15 
24. The method of claim 21, wherein at least one ofXu X2 , 
and X3 are selected from: 
20 
25 
30 
35 
40 
48 
-continued 
HOOC COOH 
h ~CH,)"NH' h ~COOH 
45 CN'>--\_} CN'>--\_} 
0 
50 
0 
55 
60 0 0 
65 
~ 
N N 
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-continued wherein when the at least one of Xu X2 , and X3 is 
0 0 
~ 
N N 
n 
He__/\ 
N N~ 
- , 
0 0 
and 
and 
10 
n is from 1 to 16, 
when the at least one of Xu X2 , and X3 is 
15 
20 n is 5, 7, or 9; 
when the at least one of Xu X2 , and X3 is 
0 
25 
30 
n is 2 or 4; 
when the at least one of Xu X2 , and X3 is 
35 
0 
40 
n is 4 or 8; 
45 
when the at least one of Xu X2 , and X3 is 
0 0 
50 
55 n is 4 or 8; and 
when the at least one of Xu X2 , and X3 is 
0 0 
n is 2 or 4, 
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25. The method of claim 21, wherein at least one ofXu X2 , 
and X3 are a methylated bidentate nitrogen heterocycle. 
26. The method of claim 21, wherein the compound further 
comprises a targeting agent. 
27. The method of claim 26, wherein the targeting agent 
selected from folate, estrogen, and erlotinib. 
28. The method of claim 21, wherein at least one of the 
ligands is a therapeutic agent. 
29. The method of claim 28, wherein the therapeutic agent 
is hydroxyquinoline. 10 
30. The method of claim 21, wherein the light includes a 
wavelength of about 350 nm to about 1000 nm. 
31. The method of claim 21, wherein the light includes a 
wavelength of about 500 nm to about 1000 nm. 
32. The method of claim 21, wherein m is less than zero. 15 
33. The method of claim 21, wherein the site is a tnmor or 
in proximity to a tumor. 
34. The method of claim 21, wherein the step of adminis-
tering includes administering the compound by oral admin-
istration, transdermal administration, administration by inha- 20 
lation, nasal administration, topical administration, 
intravaginal administration, ophthalmic administration, 
intraaural administration, intracerebral administration, rectal 
administration, and parenteral administration, including 
injectable such as intravenous administration, intra-arterial 25 
administration, intramuscular administration, subcutaneous 
administration, or combinations thereof. 
* * * * * 
